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abstract 
 
 
Hepatitis C virus (HCV) causes the most prevalent viral infection worldwide. 
Upon infection, the HCV genome is detected by the RIG-I-MAVS signalling 
pathway leading to the production of direct antiviral effectors. NS3/4A protease 
is the main inhibitor of innate immunity against HCV and it was found to inhibit 
the mitochondrial signalling protein (MAVS).  
MAVS was recently found to localize at peroxisomes coordinating with 
mitochondria the activation of effective antiviral response. Peroxisomal MAVS is 
responsible for inducing a rapid but short termed antiviral response that is IFN-
independent, contrary to mitochondrial MAVS which is associated with the 
activation of an IFN-dependent antiviral response with delayed kinetics.  
With this work we aimed at evaluating the effect of NS3/4A over the peroxisomal–
MAVS pathway. Our results showed that the MAVS localizing exclusively at 
peroxisomes is targeted by the HCV NS3/4A protease. We also show that the 
MAVS cleavage by NS3/4A impaired the antiviral response mediated by 
peroxisomal-MAVS.  
These results reaffirm the importance of peroxisomes for viral-host interaction 
and in antiviral defences. Further studies are proposed in order to better 
understand the role of this organelle in innate immunity. These may lead to the 
improvement of therapy against HCV infection. 
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resumo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O vírus da hepatite C (VHC) provoca a infeção viral mais prevalente em todo o 
mundo. Após infeção, o genoma do VHC é detetado pela via de sinalização RIG-
I-MAVS levando à produção de efetores diretos da resposta antiviral. A protease 
NS3/4A é o principal inibidor da resposta imune produzido pelo VHC e foi 
descrito como inibidor da proteína MAVS.  
A proteína MAVS foi recentemente localizada nos peroxissomas que, 
juntamente com a mitocôndria, coordenam a resposta antiviral. A MAVS 
peroxisomal é responsável pela indução de uma resposta antiviral rápida mas 
de curta duração que é independente de interferões, mas pelo contrário, a MAVS 
mitocondrial está associada a uma ativação da resposta antiviral que é 
dependente de interferões mas que se caracteriza por uma cinética retardada.  
O nosso objetivo com este trabalho consistiu em avaliar o efeito da NS3/4A na 
via de sinalização coordenada pelos peroxissomas. Os nossos resultados 
mostram que a MAVS localizada nos peroxissomas é alvo da protease NS3/4A 
do VHC. Também mostramos que a clivagem da proteína MAVS pela NS3/4A 
inibe a resposta antiviral mediada pela MAVS peroxissomal.      
Estes resultados reafirmam a importância dos peroxissomas na interação vírus-
hospedeiro e na defesa antiviral. Futuros estudos são aconselhados para que 
se compreenda a função dos peroxissomas na imunidade inata. Estes podem 
levar a uma melhoria na terapia da infeção pelo VHC. 
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I. Introduction 
1.1 Hepatitis C Virus 
1.1.1 Epidemiology and Classification 
Hepatitis C virus (HCV) was discovered in 1989 as a cause of non-A and non-B post-transfection 
hepatitis (1). Nowadays it is one of the most prevalent infections worldwide and, according to the 
World Health Organization, 130 to 170 million people are currently chronically infected and 3 to 4 
million people are newly infected each year (2). The acute infection is normally asymptomatic and 
85% develop chronic infection. Chronic infection induces chronic hepatitis, liver fibrosis and 
cirrhosis which may evolve later to hepatocellular carcinoma (3).  
HCV has been classified as part of the Hepacivirus genus from the Flaviviridae family. HCV is 
subdivided in 6 genotypes that differ according to geographic distribution, specific symptoms and 
treatment response. Each genotype can be further divided in subtypes (e.g. 1a, 1b, 2a) (4). The 
current treatment is based on a combined therapy of pegylated interferon α (Peg-IFN-α) and 
ribarin. Peg-IFN-α induces a cellular antiviral state while ribarin acts in a synergistically manner 
throw different mechanisms (e.g. modulation of interferon-stimulated gene (ISGs) expression or 
error catastrophe induction by mutagen incorporation) (5). For unknown reasons this therapy is 
less effective in infections caused by genotype 1 (sustained virological response1 less than 42%-
52%) compared with genotype 4, 5 or 6 (SVR 65%-85%) and genotype 2 or 3 (SVR 76%-80%) (6). 
Recently, direct acting antiviral agents (DAAs), such as NS3 protease and RNA polymerase 
inhibitors, were developed and when one of these is combined with the standard therapy, the 
SVR increases to 70% (7). This triple combination is only allowed in genotype 1 infected patients 
(8). However, patients can develop resistance due to numerous variants (quasi-species) that are 
produced during HCV replication because of the high replication rate and low fidelity of HCV RNA-
dependent RNA polymerase (6). Until now no vaccine is available due to the high genetic 
variability of this virus (9).  
                                                          
1 Sustained Virological Response (SVR) corresponds to an undetectable viral load six months after 
termination of treatment. 
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1.1.2. Genome 
HCV is characterized as a hepatotropic enveloped positive single-stranded RNA virus. It has a 9.6 
kb genome composed by an open reading frame, that encodes a polyprotein of 3000 amino acids 
(aa), flanked by 5’ and 3’ untranslated regions (UTR’s) at both ends that are highly structured 
structures essential for replication and translation. The 5’ UTR with 341 nucleotides (nt) allows 
the cap-independent translation of viral RNA since it contains an internal ribosomal entry site 
(IRES) that is capable of binding to the 40S ribosomal subunit leading to the formation of a stable 
pre-initiation complex (10). The 3’ UTR length can vary between 200-235 nt and its function is 
crucial for RNA replication (11). 
1.1.3. Structure and life cycle 
HCV studies are difficult to perform due to its viral low titters and poor stability (12). Nonetheless, 
in the last few years several techniques have emerged which allow the study of HCV infectivity. 
The first studies about HCV were possible due the development of functional cDNA clones that 
allowed the first molecular characterization (13). Meanwhile, HCV replication systems that used 
drug-selectable ‘subgenomic replicons’ were established and permitted study of the intracellular 
steps of HCV replication without producing infectious particles (14,15). Recently, reverse-genetics 
cell culture systems for HCV have been developed which allow the production of infectious virions 
in cell culture (designated HCVcc particles) (14). Through the association of these techniques with 
electron microscopy studies, advances in morphological studies of HCV particles were possible.  
HCV particles are different from other members of the Flaviviridae (16). HCV presents a highly 
heterogeneous structure with a proximal size ranging between 40 to 100 nm in diameter (≈50 nm 
in other members), a spherical morphology that differs from the Flaviviridae icosahedrical 
symmetry (12,17) as well as a low density oscillating between 1.06 g/mL to 1.25 g/mL (18). 
However, these characteristics are also variable between virus particles generated in cell culture 
or isolated from infected patients (19).   
HCV primarily infects hepatocytes cells of humans and chimpanzees having, however, the capacity 
to  spread through B cells, dendritic cells and other cells already reported (20). For entry, several 
potential host proteins were already proposed including the receptors human tetraspanin CD81, 
scavenger receptor class B type I (SR-BI), claudin-1 (CLDN1), mannose binding lectins DC-SIGN 
(dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) and L-SIGN 
(liver/lymph node-specific intercellular adhesion molecule-3-grabbing integrin), and the binding 
Hepatitis C virus and Peroxisomes: evasion from the cellular antiviral response 
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factors glycosaminoglycans (GAGS) and low-density lipoprotein receptor (LDLR) (21). Despite all 
the molecules described above being important and necessary for HCV entry, none of them alone 
is sufficient (22).  
The more recent model of HCV entry into hepatocytes explains that HCV particles bind to GAGs 
and LDLR until the SRB1 recognizes the HCV E2 proteins and the virion-associated lipoproteins. 
The recognition exposes CD81 binding sites to HCV E2 inducing the formation of a CD81-CLDN1 
complex that has the capacity to activate the clathrin-mediated endocytosis. However, the 
mechanism of endocytosis induction has to be further investigated (23). 
Following internalization, HCV induces a low pH environment inside the endosome which triggers 
the fusion process through the rearrangement of HCV glycoproteins. The mechanisms behind the 
HCV low pH –induced fusion still have to be elucidated, although it is believed that it is associated 
to the endosome lipid composition (20,23). Consequently, these processes lead to viral RNA 
release to the cytosol where it will be translated and replicated.   
HCV translation initiates after the release of genomic RNA into the cell cytoplasm where viral 
positive-strand HCV RNA will serve as template for HCV polyprotein synthesis in the rough ER 
(Figure 2). IRES, present in the 5’ UTR, is the key in this process inducing the formation of a stable 
pre-initiation complex by binding to the 40S ribosomal subunit. Subsequent recruitment of the 
eukaryotic initiation factor (eIF) 3 and the ternary complex eIF2-GTP-Met-tRNAi results in the 
formation of the 48S like complex. After hydrolysis and release of eIF2-GDP and eIF3, 60S 
ribosomal subunit binds to form the 80S complex (24,25). This complex has the capacity to 
continue with elongation and termination leading to viral protein translation. Translation seems 
to be influenced by viral proteins such as core protein, NS4A and NS5B (10,20) as well as by the 3’-
UTR and cellular factors (24). 
HCV RNA translation leads to the production of a large polyprotein precursor, which is processed 
co- and post-translationally into 10 viral proteins (Figure 1). The polyprotein can be separated in 
two regions the N-terminal that encodes the virion structural proteins, the highly basic core (C) 
protein and envelop glycoproteins E1 and E2, which are followed by the small integral membrane 
protein p7 that is not a component of virion structure (detailed functions on Table 1). The C-
terminal encodes the non-structural (NS) proteins NS2, NS3, NS4A NS4B, NS5A and the NS5B, 
each are responsible for the intracellular processes of the virus life cycle (detailed functions on 
Table 1). The maturation of the structural proteins is possible through host signal peptidases 
cleavage but within the NS region the cleavage is processed by two viral enzymes, the NS2 
Ana Rita Filgueiras Ferreira 
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autoprotease and the NS3/4A serine protease (26). HCV translation also produces another protein 
by ribosomal frame shift within the core gene, named F (frame shift) or ARFP (alternative reading 
frame protein) (26). 
Table 1 | Function of Hepatitis C Virus (HCV) proteins and virus cycle significance (27,28) 
HCV protein Function Virus cycle significance 
E1 Envelop 
Fusion domain 
Entry 
E2 Envelop 
Receptor Binding 
Fusion domain 
Entry 
Cores Nucleoprotein 
RNA binding 
Immune modulation 
Autophagy 
Assembly of the viral 
nucleocapsid 
p7 Calcium ion Channel (viroporin) Viral assembly 
Release 
NS2 NS2/3 autoprotease Viral assembly 
NS3 Component of NS2/3 and NS3/4A 
NTPase/helicase 
Serine protease 
RNA helicase 
HCV processing 
Immune modulation 
Replicase complex 
NS4A NS3/4A proteinase cofactor NS3 targeting to the ER 
membrane 
NS4B Remodeling od host-cell membranes Membranous web induction 
NS5A RNA replication by complexes formation    
NS5B RNA-dependent RNA polymerase Replicase complex 
 
Figure 1 | Hepatitis C virus (HCV) genome organization and polyprotein processing (20). HCV RNA genome is 
represented at the top. Genome translation into a polyprotein precursor is mediated by the internal ribosome entry site 
(IRES).HCV polyprotein contains all the non-structural and structural proteins of HCV that has to be cleaved to release 
mature proteins. The diamonds indicate the cleavage sites for host signal peptidases. Arrows indicate cleavage sites for 
NS2 and NS3/4A proteases. Dots indicate glycosylation of envelope proteins.  
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Replication Complex 
NS4B expression induces alterations in cell membranes leading to the formation of ‘sponge-like 
inclusions’ closely associated to rER and designated as membranous web (Figure 2) (29,30). These 
type of structures are induced by all positive-strand RNA viruses, including HCV, and they are 
composed by structural and non-structural proteins, replicating RNA, and altered host-cell 
membranes (30). This strategy seems to offer several advantages to viruses (30,31) such as (i) 
compartmentalization and concentration of viral products in one place, (ii) replication complex 
organization as well as physical support, (iii) tethering of viral RNA during unwinding, (iv) supply of 
lipid constituents important for replication, and (v) protection of viral RNA from host defences. 
During HCV replication, NS5B is the main character being the RNA-dependent RNA polymerase 
(RdRp) necessary for the synthesis of a complementary negative-strand RNA intermediate, that 
will serve as a template to  create several copies of the genomic positive-strand RNA. For acting as 
RdRp, NS5B is dependent of its transmembranar domain (32).  It was found that the NS3 protein 
may also be important for RNA replication by complementing the action of NS4B in inducing the 
membranous web, as well as through binding to RNA. NS3/4A has a DExH/D-box helicase domain 
that allows the binding to nucleic acids after ATP hydrolysis. This function could be important for 
separation or unwinding of local RNA or dislocation of RNA-binding proteins (8). It seems that 
NS5A phosphorylated state can regulate the RNA replication directly or indirectly through the 
binding to host proteins that are implicated in replication (33). Several host factors have been 
proposed as regulators of HCV RNA replication, including the availability of fatty acids (25,26,34). 
Regarding to NS5B’s activity as RdRp, it is important to refer that viral RNA RdRp do not have 
proofreading activity leading to a high frequency of nucleotide substitutions during replications 
(32). This means a high error or mutation rate and the consequence is the rapid generation of 
viral variants. Thus, infected individuals present heterogeneous viral microvariants of a 
predominant master sequence, referred as quasispecies (32,35). The existence of such a 
heterogeneous variants or quasispecies is associated with different biological properties and 
phenotype in the host, such as carcinogenicity or tissue tropism. Additionally, it seems to be 
correlated with resistance to IFN therapy whereas some quasispecies are more resistant to 
therapy than others (35).   
Replication and translation relationship 
HCV positive-strand RNA virus possesses the regulator elements for both replication and 
translation. Both 5’ and 3’ UTR elements induce and regulate replication and translation processes 
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in the same RNA molecule. For replication, the positive-strand RNA has to be converted in a 
complementary negative-strand RNA and this processes goes from 3’ to 5’. However, translation 
occurs in the same genome positive strand RNA in the opposite direction, from 5’ to 3’ (25). Thus, 
HCV replication and translation have to be closely regulated. 
In other positive-strand RNA viruses it was found that one of the processes was preferred 
comparing with the other. In the case of poliovirus, it has been reported that transcription was 
dependent on the translation activity whereas the translation of Sindbis virus or vesicular 
stomatitis virus has been reported to be transcriptionally dependent (25).  In HCV, it was found 
that RNA translation was dependent on active RNA synthesis. In one study, the inhibition of RNA 
synthesis decreased the HCV viral protein synthesis before a significant decrease in the amount of 
RNA had occur (36). Several proteins have been identified as possible regulators of the balance of 
these two processes, such as viral and host proteins (e.g. core protein or PKR, respectably) (25).  
Assembly and release 
Several theories about HCV assembly exist but all of them stress the interplay between the 
assembly process and the lipid metabolism (19). After post-translation modifications, the core 
protein is transported to LDs and induce its relocation in cells, changing its general distribution in 
the cytosol to a close nuclear subcellular location. Like this, LDs become closer to ER and to an  
ER-like membranous web where replication occurs (37). Although it is unknown how the 
interaction occurs, it is recognized that NS5A associated to RNA becomes close enough to allow 
the oligomerization between core protein and HCV genome (38). This interaction allows 
nucleocapsid formation (39).  
Nucleocapsids have to be encapsulated and acquire viral glycoproteins at the surface to become 
infectious viral particles. The mechanism through which it occurs is not yet established. The 
current models for envelopment suggest that nucleocapsids are incorporated in ER lumen where 
they obtain their lipid envelope by incorporation into the very-low-density-lipoproteins (VLDL) 
pathway (19). VLDL, as well LDL (low-density lipoproteins), are the major transporters and are 
produced and released by hepatocytes into the blood. Their architecture is similar to LDs: they are 
composed by a core full of triglycerides and cholesterol esters which is surrounded by a layer of 
apolipoproteins and phospholipids (40). During circulation in the blood stream they are converted 
into LDL due to exchange of lipids with tissues (41). In hepatocytes, they form in the ER lumen 
through a multistep process. Initially, apoB suffers lipidification during its transport by microsomal 
transfer protein (MTP) inside the ER lumen, forming the VLDL precursor (pre-VLDL). Further 
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lipidification of the pre-VLDL occurs within the secretory pathway forming VLDL particles, 
although the mechanisms behind it are yet to be clarified. It was hence proposed that HCV 
nucleocapsids somehow interact with VLDL incorporating the same proteins, apoB, apoE and 
MTP. This is corroborated with the findings that circulating HCV virions are associated with apoB 
and apoE and others constituents of VLDLs, this particles are termed LVPs (lipoviral-particles) (42).  
Glycoproteins E1 and E2, after translation form a non-covalent heterodimer which are retained in 
the ER lumen until HCV assembly (41). Hence, some models suggest that they are incorporated 
while the nucleocapsid envelopment occurs inside ER lumen. Some studies showed that their 
incorporation may be apoB- and apoE- dependent (19,41,43). Throughout the secretory pathway 
they suffer maturation and form large covalent complexes in the HCV virions surface, essential for 
HCV entry (39).  
 
Figure 2 | Hepatitis C virus life Cycle (20). After HCV entry into the cell (a) and uncoating (b), the HCV genome is release 
into the cytoplasm. Translation is mediated by IRES (c) and polyprotein processing as well as RNA replication occurs (d). 
Packing and assembly (e) is followed by virion maturation and release (f). It is important to refer that translation, 
replication and membranous web formations are represented as separated steps only for simplicity. These are tightly 
correlated processes that may occur in parallel.   
HCV virion budding occurs through the endosome secretory pathway that is regulated by ESCRTs 
(endosomal sorting complex required for transport) (41,43). The ESCRT pathway is responsible for 
the budding and fission of membranous compartments that curve away from the cytosol by 
incorporating target proteins into a multivesicular body for degradation. It is used by many 
enveloped viruses to bud into extracellular compartments. Through this pathway HCV release 
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does not require cell lysis and takes advantage of host cell excretory pathway to get out of the 
cell. 
1.1.5. HCV NS3/4A protease 
NS3/4A protein is a non-covalent heterodimer complex formed by two HCV proteins, NS3 serine 
protease and NS4A cofactor (44). In the N-terminal NS3 contains a serine protease and a 
NTPase/RNA helicase in the C-terminal (45). For NS3 activation and optimal function, NS4A 
protein binding is essential as it alters NS3 conformation stabilizing the catalytic centre. Several 
studies demonstrated that any substitutions in NS4A sequence lead to a decrease in NS3 activity 
(44). NS4A also has the function of tethering the holoenzyme complex to intercellular membranes 
(46). Hence, NS3 protein confers the catalytic function and NS4A consists in the activation subunit 
of this complex.  
NS3/4A is essential for HCV life cycle not only in HCV replication but also for its persistence and 
pathogenesis. During HCV polyprotein processing, this complex is responsible for the proteolytic 
cleavage of four junctions of HCV polyprotein precursor leading to the maturation HCV non-
structural proteins (NS3-4A self-cleavage, NS4A-NS4B, NS4B-NS5A, NS5A-NS5B) (Figure 1) (47).  As 
indicated in the previous sections, NS3/4A also intervene in HCV genome replication as well as in 
viral assembly processes.  
NS3/4A complex is also essential for HCV evasion to host cellular defences (44). Several studies 
have shown that NS3/4A blocked TLR3 and RIG-I pathways impairing the induction of IFN-antiviral 
response at the cellular level (for further details read the next section) (46,48).  Moreover it was 
found that NS3/4A also inhibits the systemic innate immunity through the cleavage of the 
complement system component 4, mainly produced by hepatocytes (49,50).  
1.2. Innate Immune Response 
The innate immune system expresses different pattern recognition receptors (PRRs) that 
recognize essential compounds of the pathogen’s structure, named pathogen-associated 
molecular patterns (PAMPs) (51). PRRs can be associated to cell membranes (membrane-bond 
PRR), intracellular compartments (cytosolic PRR), secreted into the blood stream or into tissue 
fluids (secreted PRR and phagocytic PRR) (50,52). These receptors have as main functions the 
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opsonisation of pathogens, activation of complement and coagulation cascades, phagocytosis, 
activation of proinflammatory signalling pathways and induction of apoptosis (52).  
1.2.1. Cellular Antiviral Defence 
Viruses are highly infectious microorganisms completely dependent on the host cell machinery. 
Viruses exploit and reprogram the host metabolism to replicate, which can lead to the host’s 
death. However, throughout evolution, viruses and host co-existence always has been dependent 
of each other’s survival, resulting in a gain of strategies to antagonize each other and promote 
their own survival (53).  
Viral infection induces a set of intracellular responses that results in the production of antiviral 
molecules that compose the first line of immune defence. The host response to infection aims to 
abort viral replication and inhibit virions production, constricting infection to other cells (52). 
Intracellular PRRs recognize viral PAMPs that mainly consist of viral nucleic acids, such as 5’ 
triphosphate terminal RNA and the presence of DNA in cytoplasm, with specific signatures, 
allowing the differentiation between non-self and host nucleic acids (52,54). This recognition is 
possible due to a variety of receptors, such as the endosomal Toll-like receptors (55,56), cytosolic 
DNA sensors and the cytosolic RIG-I-like family (RLRs) (57). 
Toll-like receptors were first discovered in drosophila embryos and their important role in 
immune defence against bacterial and fungal infections was establish in adult fly’s (58). 
Mammalian homologs were identified later, existing 10 TLRs in humans and 13 TLRs in mice. 
These TLRs differ in ligand specificity, expression pattern and target genes – TLR1, TLR2, TLR4, 
TLR5, and TLR6 are present in plasma membrane and the TLR3, TLR7, TLR8, TLR9 are present at 
endosomal membrane. In viral infection, additionally to viral nucleic acids recognition by 
endosomal TLR - TLR3 recognize dsRNA, TLR7 and TLR 8 ssRNA and TLR9 recognizes CpG DNA - the 
TLR2 and TLR4 present at the plasma membrane can also recognize viral proteins from the viral 
external structure (54,58). TLR activation by PAMPs culminates in the activation of transcription 
factors through the activation of a variety of adaptor molecules, which differ according to the 
specific TLR that induces the cascade. These transcription factors regulate the expression of 
interferon, cytokines and chemokines and also seem to influence cellular maturation and survival 
(54). 
In eukaryotic cells, DNA is confined within the nucleus and mitochondria, thus the presence of 
DNA in cytoplasm is an aberrant situation. There is a variety of cytosolic DNA sensors that 
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recognize non-self B-form dsDNA that is common to viruses, bacteria and apoptotic cells. This 
recognition induces a robust immune response, including inflammasome activation and type-I IFN 
expression (59). Some of these receptors were identified: DAI and STING, that stimulate the TBK1-
IRF3 axis after recognition of dsDNA; RNA polymerase III (Pol III), which uses AT-rich and 
herpesvirus dsDNA as a template for 5’ triphosphate RNAs production; PYHIN family, a group of 
proteins that possess a domain capable of DNA binding and a domain that allows protein-protein 
interactions, including AIM2 and IFI16 proteins. Concerning viral recognition by cytosolic DNA 
sensors, the specific sensor that mediates recognition is dependent of the expression pattern of 
these in each cell type (60).  
RIG-I-like family 
RIG-I-like receptors (RLR) family consists in three molecules termed retinoic acid-inducible gene 
(RIG-I), melanoma differentiation-associated gene-5 (MDA5) and laboratory of genetics and 
physiology 2 (LGP2) (57). They are characterized by a DExD/H-box helicase domain. RIG-I and 
MDA5 also contain an N-terminal tandem caspase activation and recruitment domain (CARD). 
RIG-I, MDA5 and LGP2 have a C-terminal domain (CTD, known also as RD=repressor domain).  
During viral infection, RIG-I and MDA5 can recognize viral RNA released into the cytosol. This 
recognition is mediated by the DExD/H-helicase box domain and triggers the production of type-I 
IFN (61). The RD of RIG-I inhibits the activation of the downstream signalling being necessary the 
activating ligand in order to induce a conformational alteration to expose the RIG-I CARD domains 
(54,62). Opposing to RIG-I, MDA5 does not undergo a conformational alteration, being the CARD 
domains permanently exposed. LGP2 function in immune response is not well understood. The 
lack of CARDs and the presence of helicase and CTD suggests a possible regulatory function. Some 
studies indicate that LGP2 can either enhance or inhibit the function of RIG-I and MDA5 (8).  
RIG-I and MDA5 have specific ligands that allow specific viral recognition (Figure 3).  RIG-I 
recognizes viral genome that contains 5’-triphosphate ssRNA, base pairing at the 5’-end due to 
secondary dsRNA structures or short RNA sequences while MDA5 recognizes long or with high 
molecular weight dsRNA sequences. 
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Figure 3 | Viruses recognized by RIG-I and MDA5 and evasion to RLR recognition (Adapted from Schlee M. 2013)  (8). 
ss: single stranded, ds: souble stranded, (+): positive strand genome, (−): negative strand genome 
MAVS Signalling 
Mitochondrial antiviral signalling (MAVS (63), also known as card adaptor inducing IFN-β=CARDIF 
(64), IFN-β promoter stimulator 1=IPS-1 (65) or virus-induced signalling adaptor=VISA (66)) was 
described as an adaptor protein with 540 aa in the RLR antiviral pathway. MAVS N-terminal 
contains a CARD-like domain and a proline-rich region, whereas the C-terminal consists in a 
hydrophobic transmembrane domain that targets the protein to the respective intracellular 
membranes (mitochondria (63), peroxisomes (67), and mitochondria-associated membranes 
(MAM) (68)).  Deletion studies revealed that both N-terminal CARD domain and C-terminal are 
essential for MAVS function (63). Upon RIG-I activation by viral RNA recognition, MAVS is 
activated by receiving the RIG-I stimulus through the CARD domain. MAVS activation induces the 
formation of a detergent-resistant oligomers that may involve the CARD domains of several MAVS 
(63,69,70).  
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Figure 4 | Schematic representation of MAVS pathway  (67,71,72).  RIG-I and/or MDA5 recognize viral RNA which 
leads to MAVS activation through CARD domains interaction. Mitochondrial-MAVS pathway triggers the expression of 
type I IFNs through the formation of an enhanceosome composed by the transcription factors AP-1, IRF3, IRF7 and NF-
κB. These transcription factors are activated by the kinases TBK1 and IKK. Peroxisomal-MAVS pathway induces the 
dimerization of IRF3 with IRF1 that are essential for direct and IFN-independent ISGs expression. Peroxisomal MAVS 
may have a role in type III IFN expression. 
MAVS is present in the outer membrane of mitochondria (63), peroxisomes (67), and 
mitochondria-associated membranes (MAMs), which interconnects mitochondria and 
peroxisomes (68). The signalling pathway downstream of MAVS remains to be fully understood, 
being the mitochondrial-MAVS pathways better described. However, it has already been 
identified that both peroxisomal and mitochondrial MAVS have specific signalling pathways which 
result in a different but complementary response (67). Peroxisomal MAVS is associated to a rapid 
but short-termed induction of interferon stimulated genes (ISGs) that it is IFN-independent while 
mitochondrial MAVS is responsible for the production of ISGs in a IFN-dependent manner with 
delayed kinetics (67).  In the mitochondrial MAVS pathway some downstream molecules were 
already identified (Figure 4). MAVS oligomerization induces via TRAF6 and/or TRAF3, the 
activation of TBK1 and IKK kinases. These kinases are responsible for regulating the transcription 
factors that form the enhanceosome (NF-κB, interferon regulatory factor (IRF) 3 and 7, and AP-1) 
? 
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that activates type I IFNs expression (73). Regarding the peroxisomal MAVS a lot is still to be 
investigated but a new study shed some light over the downstream effectors of peroxisomal-
MAVS pathway (Figure 4) (71). When MAVS was discovered at peroxisomes it was also revealed 
that IRF1 may take a role in the direct and IFN-independent induction of ISGs, through 
dimerization with IRF3 (67). Later it was also demonstrated that RLR could drive type III IFN 
expression through peroxisomal-MAVS pathway and IRF1 could be the regulator of this response 
(71). It was accepted that peroxisomal MAVS could drive the activation of NF-κB and IRF3 that in 
coordination with other pathways can promote the formation of the enhanceosome and prelude 
in type I IFNs expression. However, is still unknown how these different responses are 
coordinated and how they induce different cellular responses in the fight against viruses (71). 
1.2.2. Cellular antiviral response to HCV and viral evasion 
HCV infection is mainly sensed by RLR family and TLR3.These PRRs sense dsRNA that accumulates 
in cytoplasm during infection or that is present inside the endosome by uptake of dying cells. This 
recognition activates specific signalling cascades that culminate with IFN-β and proinflamatory 
cytokine production through the induction of antiviral and immunomodulatory genes. Type III 
interferons are also activated, however the activation mechanism is not well understood. It was 
already described that this immune response to HCV infection is set rapidly, even before 
extensive viral synthesis (74). IFNs production induces the production of ISGs and several of these 
were already associated to the suppression of HCV replication. This suppression is possible due to 
the action of multiple ISGs that target different steps of HCV life cycle (e.g. IRF1 acts in HCV 
translation and RNA replication but viperin only acts against RNA replication) (75).   
During acute HCV infection and in cases of high initial viremia, HCV can be cleared spontaneously, 
suggesting that a rapid response of PRRs and innate immune induction can control acute HCV 
infection. However, 80% of HCV infected patients do not effectively control the virus and develop 
chronic infection (76). This evolution is associated with the evolutionary adaptation of HCV which 
developed innate immune evasion mechanisms. HCV NS3/4A protease, as already described 
(section 1.1.5), efficiently cleaves two important antiviral signalling molecules after HCV PAMPs 
recognition by host PRRs: MAVS protein of RLR pathway and TRIF, a TLR adaptor protein (77). This 
complex disables two important antiviral signalling pathways, inhibiting IFNs production. HCV also 
targets PKR, another PRR that is also activated during infection. PKR acts by suppressing host-
mRNA translation and consequently viral translation is also impaired. However, HCV regulation of 
PKR activity is complex and it has to be further investigated (76). 
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Nevertheless, the innate immune system is capable of reacting to infection leading to the 
production of hundreds of type I and/or type III induced ISGs. This response controls the infection 
to some extent but it is not sufficient to eliminate HCV. Additionally, patients with high levels of 
ISGs do not respond to treatments with the common antivirals (78).   
1.3. Peroxisomes  
Peroxisomes are highly dynamic, multifunctional and ubiquitous organelles present in eukaryotic 
cells and play diverse metabolic roles depending on the cells type. Independent of the cell origin, 
all peroxisomes share the two main biochemical functions: hydrogen peroxide (H2O2) metabolism 
and fatty acid oxidation (79). Peroxisomes interact functionally and morphologically with other 
organelles such as ER, mitochondria and lipid droplets (80).  
 
Figure 5 | Schematic view of peroxisomes structure and functions (81).  
Peroxisomes’ shape and size vary greatly in different tissues, ranging from a spherical to rod-like 
form and from 0.1 to 0.5 μm in diameter, but they can also appear as elongated tubular 
organelles (up to 5 μm) (81). Their structure consists in a single lipid membrane that surrounds a 
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granular matrix, devoid of DNA or protein synthesis machinery (Figure 5). Peroxisomes proteins 
are encoded by nuclear genes and synthesized in cell cytoplasm by polyribosomes (79).  
Since their discovery in the 1965 a lot was learned about peroxisomes and it is now known that 
they are essential for human health and development (82). A group of inherited peroxisomal 
disorders in humans was discover and they are characterized by severe metabolic dysfunctions 
and neurological and developmental defects (83–85).  
1.3.1. Structure  
Biogenesis 
Peroxisomes can arise from de novo formation or by growth and division from pre-existing 
organelles (Figure 6) (83).  
The de novo formation of peroxisomes from ER was found after the reintroduction of deficient 
genes (encoding the membrane biogenesis/import factors Pex19, Pex3 or Pex16) in mutant cells 
lacking peroxisomes or in yeast mutants lacking peroxisomes due to a defect in 
segregation/inheritance (86). It was also reported that artificial targeting of Pex3 to mitochondria 
also induced the de novo synthesis of peroxisomes from mitochondria membrane, suggesting that 
natural or artificial targeting of Pex3 to any endomembrane may initiate peroxisome biosynthesis 
(87).   
In mammalian cells, as well as in plants and fungi cells, peroxisomes normally multiply from 
growth and division where a sequence of morphological alterations occur, including elongation, 
membrane constriction and final fission (88). Peroxisome membrane elongation requires Pex11, a 
peroxisomal membrane protein (PMP). The following final fission process depends on the 
dynamin-related-protein GTPase DLP/DRP1 and its membrane adaptors Fis1 and MFF in 
mammals. This machinery is shared with mitochondria, a common feature in mammals, fungi and 
plants (88).  
Both peroxisomal formation processes, either from ER or by growth and division, follow the same 
maturation process in order to convert peroxisomes in a mature and metabolic active organelle. 
The maturation process is achieved through the selective and stepwise import of certain PMPs, 
membrane lipids and matrix proteins (89). 
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Figure 6 | Potential pathways to peroxisomal biogenesis (81). (A) Peroxisomes are generated autonomously through 
division of pre-existing organelles (top) or through a de novo process involving budding from the ER followed by import 
of matrix proteins (bottom). (B) Peroxisomal membrane protein import. PMPs are imported post-translationally to the 
peroxisomal membrane. Pex19 is a soluble chaperone that binds to PMPs and transports them to the peroxisomal 
membrane, where it docks with a complex containing Pex16 and Pex3. Following insertion of the PMP, PEx19 is recycled 
back to the cytosol. 
Synthesis of peroxisomal matrix proteins occur on free ribosomes in the cytosol being then post-
translationally imported into the organelle. Proteins that present one of two peroxisomal 
targeting signals (PTS1 and PTS2) are recognized by soluble receptors (Pex5 and Pex7, 
respectively), that transport them to docking sites present at the peroxisomal membrane. After 
recognition, the receptor-cargo complex is translocated into the luminal side of peroxisomes, 
cargo is released and receptors are shuttle back to the cytosol. The importer mechanism for PMPs 
requires a different and less characterized protein machinery that involves the cytosolic 
receptor/chaperone Pex19 (Figure 6). The complex formed by Pex19-PMP interacts with Pex3 and 
Pex16 which mediate insertion into the peroxisome membrane (88,90).  
Modulation of peroxisome number and morphology 
Peroxisomes react to physiological changes in their cellular environment, such as starvation, 
infection and cell death, adapting their abundance, morphology, distribution and enzyme content 
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accordingly. Peroxisomes proliferation is associated to an increased synthesis of peroxisomal 
enzymes. Moreover their proliferation is associated to a first elongation and posterior division. 
These responses of peroxisomes to alterations in their environment were verified in situations 
where hypolipidemic drugs or fatty acids were added as well as in cold or environmental 
pollutants exposition (91). It seems that, in mammalian cells, these compounds mimic the natural 
ligands (e.g. fatty acids, hypolipidemic fibrates) of the nuclear transcription factor peroxisome 
proliferator activated receptor (PPAR)-α. PPRs form heterodimers with retinoid X receptors (RXRs) 
and induce the transcription of peroxisomal genes involved in β-oxidation and proliferation by 
binding to specific DNA-sequences known as peroxisome proliferator response elements (PPRs)  
Autophagy 
When the requirement for peroxisomal proliferation disappears the excess of peroxisomes is 
removed by autophagy. Autophagy is a process regulated by ATG genes that induces 
sequestration and degradation of cell organelles, and other components, within lysosomes or 
vacuoles. There is two mechanisms for autophagy: macroautophagy and microautophagy. 
Macroautophagy consists in sequestering cell components within autophagosomes which then 
fuse with lysosomes/vacuoles, whereas in microautophagy cell components are engulfed by a 
lysosome/vacuole forming microautophagyc bodies (91,92).  
1.3.2. Functions 
Peroxisomes were identified by Christian De Duve in 1965 after isolating the organelle from rat 
liver and observing the co-localization between several H2O2-producing oxidases, as well as 
catalase, H2O2-degrading enzyme, with the organelle matrix (93). Since then, several new 
functions were attributed to peroxisomes. In the different organisms, peroxisomes develop a 
series of specialized functions: in fungi they are responsible for the biosynthesis of penicillin and 
degradation of methanol, in trypanosomes they perform glycolysis, in plants photorespiration and 
glyoxylate cycle, and in mammals they synthetize plasmalogens. Plasmalogens are etherlipids that 
make the neuronal myelin sheaths in the brain that, in case of loss of peroxisomal functions, is 
often associated with neurodegenerative processes. In mammals they are also involved in the 
synthesis of bile acids and docosahexanoic acid (neuromodulator), fatty acid elongation, α- and β-
oxidation of certain fatty acids, metabolism of amino acids, catabolism of purines, polyamines, 
and mediators of inflammation such as prostaglandins and eicosanoids (83).  
 
Ana Rita Filgueiras Ferreira 
26 
 
1. Peroxisome lipid metabolism 
Peroxisomes are responsible for fatty acid β-oxidation, fatty acid α-oxidation, and ether 
phospholipids biosynthesis (Figure 7). In plants and fungi cells, peroxisomes are the only organelle 
responsible for fatty acid metabolism, although in animal cells, fatty acid oxidation also occurs 
through the coordination between peroxisomes and mitochondria (94). For a long time, it was 
though that peroxisomal β-oxidation was an auxiliary system for the mitochondrial β-oxidation 
pathway in case of fatty acid overload. This notion was refuted by the discovery of elevated very 
long chain fatty acids (VLCFAs) levels in patients with peroxisomal abnormalities, suggesting that 
peroxisomes have their own role in β-oxidation (95). This led to the discovery of specific 
substrates for both mitochondrial and peroxisomal β-oxidation (96).  
The process of β-oxidation involves four main reactions: 1) dehydrogenation, 2) hydration, 3) 
dehydrogenation, and 4) thiolytic cleavage (80). In each cycle fatty acids are shortened by two 
carbons atoms which are released as acetyl-coenzyme A (acetyl-CoA). However, β-oxidation 
cannot be completed in peroxisomes being acyl-CoA esters shuttled to mitochondria for further 
oxidation (95). Peroxisomal β-oxidation is a heat-generating process contributing for 
thermogenesis. In the 1st phase of oxidation, electrons released from FAD-linked oxidases are 
donated to an oxygen producing H2O2, and in the 2nd phase electrons are taken by NAD+, that has 
to be reoxidized in mitochondria (Figure 7) (97). 
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Figure 7 | Peroxisomal fatty acid β-oxidation pathways (Adapted from Camões el al. 2014) (98).  
2. ROS metabolism in peroxisomes 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) consist in by-products of 
metabolic reactions, like H2O2 produced by peroxisomes. To counterbalance the production of 
negative molecules and protect cells, peroxisomes also have mechanisms to counteract oxidative 
stress and maintain redox homeostasis (99). Catalase, alongside with other enzymes, is an anti-
oxidant enzyme present in the matrix of peroxisomes that allow peroxisomes to participate in cell 
response to stress. Catalase acts by converting H2O2 into water and O2, additionally catalase also 
metabolize ethanol, methanol, phenols and nitrites (99,100). ROS participate in several cell 
signalling pathways but overproduction can induce oxidative modifications of different molecules, 
such as proteins, lipids and nucleic acids, and under oxidative stress conditions can lead to diverse 
pathological conditions (97).  
Ana Rita Filgueiras Ferreira 
28 
 
1.3.3. Peroxisomes in health and disease 
Given the important roles of peroxisomes in cellular metabolism, their dysfunction can lead to 
severe neurological and developmental disorders (101) 
The peroxisomal disorders represent a group of genetic diseases associated to the impairment of 
one or more peroxisomal functions. They are subdivided into three subgroups: 1) the peroxisome 
biogenesis disorders; 2) the single peroxisomal enzyme deficiencies; 3) the single peroxisomal 
substrate transport deficiencies (84). The discovery of these different types of disorders 
associated to peroxisomes helped in the sorting of essential peroxisomal components in health 
and disease. The important role of peroxisomes in β-oxidation was discover after the 
identification of a patient where VLCFA accumulate in cells due to a peroxisomal dysfunction. This 
pathology was named as Zellweger syndrome, and it is characterized by the absence of 
morphologically identifiable peroxisomes. In patients with this disorder it was also found a 
deficiency of plasmogens, phospholypids important for neural tissue and also present in 
erythrocytes (85).  
Peroxisomes are also important for ROS metabolism, as indicated previously. Any dysfunction in 
ROS metabolism can also induce the onset of several neurodegenerative as Parkinson’s Disease, 
Alzheimer’s disease, as well as cancer and ageing (96).   
As already described in the section 1.2 of introduction, peroxisomes are also associated to the 
coordination of antiviral signalling with mitochondria. Moreover, it was also detected that 
peroxisomal morphology suffers some alteration. Dixiet et al. (2010) described that reovirus 
infection induced peroxisomal aggregation and the formation of peroxisomal tubules. These 
alterations were correlated with the peroxisomal-MAVS signalling activation during infection (67). 
Another example is the use of peroxisomes as replication site. In infections caused by members of 
the tombusvirus family it was detected that p33, a member of the replication complex, associated 
with plant peroxisomes (102). Other viruses like HIV and influenza express proteins that were 
found at peroxisomes (103). 
Thus, peroxisomes are essential organelles for cells having specific and important functions. They 
coordinate with others organelles, like mitochondria, ER and lipid droplets various signalling 
cascades. Lately, peroxisomes have been associated with viral-host interactions, however their 
function during infection is still elusive.  
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II. Objectives 
HCV is a major human viral pathogen that infects hepatocytes causing liver cirrhosis, chronic 
hepatitis and hepatocellular carcinoma. Since HCV discover in 1989 a lot has been learned about 
its life cycle and host-interaction, however several pathways have to be better elucidated, such as 
cell recognition and entry, factors that regulate replication and translation, or even virion 
assembly. HCV is highly dependent of cellular lipid metabolism - virions incorporate lipids in their 
structure and associate with lipoproteins what may increase HCV infectivity.  
Until recently, peroxisomes were thought to be an auxiliary organelle to mitochondrial pathways 
in cellular metabolism. However, the existence of pathologies that occur due to a malfunction or 
inexistence of peroxisomes in cells rise the importance of peroxisomes in health and disease. 
Additionally, recent studies showed that peroxisomes are also involved in the coordination of the 
cellular antiviral response.  
MAVS is a protein adaptor in the antiviral pathway activated by RLRs. MAVS was first described at 
mitochondria and was recently found to be also localized at peroxisomes. Both organelles 
coordinate MAVS pathway during viral infection acting differently but in a complementing way.  
The main objective of this project is to characterize the importance of peroxisomes in antiviral 
immunity against HCV. For this, I will investigate the effect of NS3/4A, a protease that allows HCV 
evasion, in HCV evasion from the cellular antiviral defence coordinated by peroxisomal MAVS. It 
was already described that this complex target MAVS at mitochondria, however nothing is known 
concerning it targeting of peroxisomal. 
To achieve this objective the following specific aims were proposed: 
1. Development of a MAVS construct that is targeted exclusively to peroxisomes and contains the 
recognition site for HCV NS3/4A cleavage; 
2. Examine the localization at peroxisomes of the construct developed; 
3. Identify the effect of NS3/4A over the peroxisomal MAVS; 
4. Evaluate if MAVS cleavage by NS3/4A impairs the cellular antiviral response.  
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III. Material and Methods 
3.1. Material 
3.1.1. Bacterial Strains 
 E.coli XL-Blue, Stratagene 
3.1.2. Vectors 
 pEGFP-C1 
 pCMV-C3 
3.1.3. Plasmids 
 pEGFP-C1-MAVS-WT 
 pCMV-C3-MAVS-WT 
 pCMV-C3-MAVS511Pex 
 pEGFP-C1-NS3/4A 
 pEGFP-C1-RIG-I-CARD 
3.1.4. Chemicals and reagents 
 Acetic Acid, Merck Millipore 
 Acrilamide, Fisher Scientific 
 Agar, Formedium 
 Agarose, Roth 
 Ammonium Persulfate (APS), Sigma 
 Bovine serum albumin (BSA), NZYTech 
 Bromophenol Blue, Sigma 
 Chloroform, Merck Millipore 
 Dimetilsulfóxido (DMSO), EMD Chemicals  
 Dithiothreitol (DTT), Sigma 
 Ethanol, Merck Millipore 
 Ethylenediaminetetraacetic acid (EDTA), Sigma 
 Ethidium Bromide, Sigma 
 Foy, Schwarz-Pharma 
 Glucose, Fluka 
 Glycerol, Roth 
 Glycine, Fisher Scientific 
 Hydrochloric acid (HCl), Merck Millipore 
 Isopropanol, Merck Millipore 
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 Kanamycin (Kan), Sigma 
 Lysogeny broth (LB), Fisher Scientific 
 Methanol, Merck Millipore 
 Midori Green Advance, Nippon Genetics  
 Milk, Néstle 
 Mowiol, Applichem 
 N-propyl-gallacte, Fluka 
 Paraformaldehyde (PFA), Sigma 
 Potassium chloride (KCl), Sigma 
 Penicillin/ Streptomycin, Labclinics 
 Phenylmethylsulfonyl fluoride (PMSF), Sigma 
 RNAse free water, Fisher Scientific 
 Sodium chloride (NaCl), Sigma 
 Sodium dodecyl sulfate (SDS), Sigma  
 Sodium Deoxylacholat, Sigma 
 Sodium phosphate (NaHPO4), Sigma 
 iTaq™ Universal SYBR® Green Supermix, BioRad 
 Tetramethylethylenediamine (TEMED), Fluka 
 Trifast, PeqLab 
 Tris, Fischer Scientific 
 Trasylol, Bayer 
 Triton, Sigma 
 Tween-20, Sigma 
 β-Mercaptoethanol, Sigma 
3.1.5. Solutions and buffers 
 BSA 1%: 2% BSA diluted in 1x PBS 
 Blotting Buffer: 0.05 M Tris, 0.4 M Glicina, 0.05% SDS, 20% Methanol 
 LB/Agar: 2 g agar, 20 g LB, 1000 mL ddH2O 
 Lysis Buffer: 25 mM Tris-HCl pH 8, 50 mM NaCl, 0.5% Sodium Deoxylacholat, 1.5 mM 
Triton X-100 
 Add protease inhibitors before use: 0.01 mM Foy, 0,25 (v/v) Trosylol, 0,1 mM PMSF 
 Loading buffer: 1 M Tris pH 6.80, 10% Glycerol, 1 M DTT, 20% SDS,  β-Mercaptoethanol, 
0.1% Bromophenol Blue 
 Mounting Medium 
 N-propyl-Gallat: 2.5% (w/v) n-propyl-gallat; 50% glycerol, in PBS 
 Mowiol: 12 g Mowiol 4-88, 20 mL Glycerol, 40 mL PBS 
 Mounting medium: 3:1 mixture Mowiol with n-propyl-gallate 
 PFA 4 %: 20 g PFA in 450 mL ddH2O, 4 drops 1 M NaOH, 50 mL 10x PBS 
 1x PBS: 1.39 M NaCl, 80 mM NaHPO4, 0.0268 M KCl, 0.0147 M KH2PO4 pH 7.36, prepared 
from 10x PBS  diluted in ddH2O 
 Running Buffer 1x: 250 mM Tris, 1.9 M Glycin, 1% SDS  
 Solution I: 50 mM glucose, 25 mM Tris-HCl pH 8, 10 mM EDTA 
 Solution II: 0,2 M NaOH, 1% SDS 
 Solution III: 60 mL 5 M KAc, 11.5 mL glacial acetic acid, 28.5 mL ddH2O 
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 Stripping Solution: 62.5 mM Tris-HCl pH 6, 2% SDS, 100 mM β-Mercaptoethanol 
 1x TAE: 0.04 M Tris, 0.02 M Acetic Acid, 1 mM EDTA pH 8, prepared from TAE 50x diluted 
in ddH2O 
 1x TBS-T: 100 mM Tris pH 8, 1,5 M NaCl, 0,05% Tween20, prepared from 10x TBS-T 
diluted in ddH2O 
 0,2%Triton X-100: 0.2% Tx-100 in 1x PBS 
3.1.6. Kits 
 Clarity Western ECL Substrate, BioRad 
 NucleoBond Xtra Midi, Macherey-Nagel 
 NucleoSpin Plasmid, Macherey-Nagel 
 NucleoSpin Gel and PCR clean-up, Macherey-Nagel 
 6x Orange DNA Loading Dye, Fermentas  
 KOD Hot Start DNA Polymerase, Novagen 
 Neon Transfection System Kit, Invitrogen 
3.1.7. Enzymes and Markers 
Enzymes 
Table 2 | Detailed information about enzymes. 
Enzyme Sequence (5’- 3’) Buffer Manufacture 
EcoRI G|AATTC 
NeBuffer 2 
New England 
BioLabs 
HindIII A|AGCTT 
KpnI GGTAC|C 
XhoI C|TCGAG 
T4 DNA Ligase - 10x T4 DNA Ligase Reaction Buffer 
M-MuLV Reverse 
Transcriptase 
- 10x M-MuL V Reverse transcription Buffer 
 Markers 
 O’GeneRuler DNA Ladder Mix, Fermentas 
 NZYColour Protein Marker II, NZYtech 
3.1.8. Membranes 
 Protran BA85 Nitrocellulose Blotting Membrane, GE Healthcare 
3.1.9. Equipment 
 My Cycler Thermal Cycler, BioRad 
 PowerPac HC High-Current Power Supply, BioRad 
 Mini-PROTEAN Tetra Cell and blotting module, BioRad  
 Electrophoresis Power Suply EPS 3501 XL Power Supply, GE Healthcare 
 Centrifuge Heraeus Pico and Fresco 17, Thermo Scientific 
 Molecular Imager GelDoc, BioRad 
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 Electromagnetic agitator VMS-C7, VWR 
 UV-3100 PC Spectrophotometer, VWR 
 Incubation shaker CERTOMAT BS-1, Sartorius 
 Olympus IX81 microscope, Olympus Optical 
 Leica TCS SP5 confocal microscope, Leica Microsystems 
 GS-710 calibrated Imaging Densitometer, BioRad 
 Vaccum gas pump, VWR 
 Shaker, Mini-Rocker PMR-30, Grant Bio  
 Water Bath VW36, VWR 
 Pipettes Eppendorf Research, Eppendorf 
 Basic pH meter PB-11, Sartorius 
 Vertical Laminar Flow Hood HERASafe, Heraeus 
 CO2 incubator MCO-17AIC, Sanyo 
 Inverted microscope Leica DM IL LED, Leica 
 Analytical balance VWR, Sartorius 
 Thermomixer Comfort 1.5, Eppendorf 
 Neon Transfection System, Invitrogen 
 7500 Real-Time PCR System, Applied Biosystems 
3.1.10. Databases and Software 
 Image Lab, BioRad 
 Quantity One 1-D Analysis Software, BioRad 
 LAS AF LITE, Leica 
 Basic Local Alignment Search (BLAST) Tool, National Center for Biotechnology Information 
(NCBI) 
 FinchTV 1.4.0 program, Geospiza 
 Excel, Microsoft 
 Serial Cloner 
3.1.11. Cells strain 
 MEF KO MAVS (kindly provided by Dr. Kagan (Harvard Medical School, USA)) 
3.1.12. Culture cell solutions and plates 
 Dulbecco’s Modified Eagle Medium (DMEM) High Glucose w/ L-Glutamine w/o Sodium 
Pyruvate, BioWest 
 Dulbecco's Phosphate Buffered Saline w/o Calcium w/o Magnesium, BioWest 
 Trypsin-EDTA 1X in PBS w/o Calcium w/o Magnesium w/o Phenol Red, BioWest 
 Fetal Bovine Serum (FBS), qualified, E.U.-approved, South America origin, Gibco 
 Opti-MEM Reduced-Serum Medium (1x) liquid, Gibco 
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3.1.13. Transfection Reagents 
 Lipofectamine 3000 Transfection Reagent, Invitrogen 
3.1.14. Primers 
Table 3 | List of primers used. 
Primer Sequence (5’-3’) Manufacture 
Primer FW 1 CC CAA GCT TGG ATG CCG TTT GCT GAA GAC 
Eurofins 
Primer RV 2 C ATG CAC AAT GGG CCT GTG GCA TGC 
Primer FW 3 GC CAC AGG CCC ATT GTG CAT GCA TTT GCC 
Primer RV 4 G GGGTAC CTC GAG TTA AGA TTT TGC TGA GG 
Primer FW Ns3 C CC CAA GCT TGG ATG GCG CCC ATC ACC 
Primer RV Ns3 G GGG TAC CTC GAG TTA GCA CTC TTC CAT CTC 
Oligo-dT primer - 
Viperin mouse Fw TGTGAGCATAGTGAGCAATGG 
Viperin mouse RV TGTCGCAGGAGATAGCAAGA 
IRF 1 mouse FW GGTCAGGACTTGGATATGGAA 
IRF 1 mouse RV AGTGGTGCTATCTGGTATAATGT 
GAPDH mouse FW AGTATGTCGTGGAGTCTA 
GAPDH mouse RV CAATCTTGAGTGAGTTGTC 
 
3.1.15. Antibodies 
Table 4 | Information of primary and secondary antibodies. 
Antibody Species Production 
Dilution 
Company Code 
IMF WB 
Primary Antibody 
Pex14 Rabbit  1:1400 - 
Provided by Dr. Crane  
(Eskitis Institut, Australia) 
PMP70 mouse monoclonal 1:200 - Sigma SAB4200181 
TOM20 
mouse monoclonal 1:100 - BD Biosciences  612278 
rabbit polyclonal 1:100 - Sigma  HPA011562 
Myc 
rabbit monoclonal 1:200 1:1000 Cell Signaling 2278 
mouse monoclonal 1:200 - Santa Cruz Biotecnhology, Inc sc-40 
MAVS mouse monoclonal - 1:2000 Santa Cruz Biotechnology, Inc.  sc-166583 
GFP rabbit monoclonal 1:200 1:4000 Invitrogen - Molecular Probles polyclonal 
Tubulin mouse monoclonal - 1:4000 Sigma T9026 
IRF-1 rabbit polyclonal - 1.1000 Santa Cruz Biotecnhology, Inc.  sc-640 
RIG-I mouse - - 1:500 
Provided by Dr. Weber  
(Institute of Virology, Germany) 
Viperin mouse - - 1:500 
Provided by Dr. Cresswell  
(Yale University, USA) 
Flag rabbit monoclonal 1:750 1:1000 Sigma F7425 
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Secondary Antibody 
Alexa 488 
rabbit 
- 
1:400 - Invitrogen - Molecular Probles A21206 
mouse 1:400 - Invitrogen - Molecular Probles A21202 
Tritc 
rabbit 1:100 - Jackson Imunoresearch 111-026-003 
mouse 1:100 - Jackson Imunoresearch 715-025-150 
Alexa 647 rabbit 1:150 - Provided by Dra. Carvalho (CNC, Portugal) 
HRP rabbit - 1:5000 BioRad 170-6515 
HRP mouse - 1:5000 BioRad 170-6516 
HoechstDye 
(1mg/mL) 
- 1:2000 - Jackson Imunoresearch 
711-475-152 
3.2.  Methods 
3.2.1. Cloning 
 Amplification of MAVS511Pex and NS3/4A 
MAVS-511-Pex 
For the development of this work, we had to develop a specific construct named MAVS511Pex. 
This construct consists in the sequence of MAVS that encodes the first 511 aa and a 
transmembrane domain from Pex13 that redirects the protein for peroxisomes. The development 
of this clone was possible due to a successive set of amplifications in which templates were the 
MAVS-WT and MAVS-Pex described in Dixit et al. (2010) and kindly provided by Dr. Kagan 
(Harvard Medical School, USA). Thus, we first amplified the sequence that encodes the first 511 aa 
from MAVS-WT using the forward primer 5’ CC CAA GCT TGG ATG CCG TTT GCT GAA GAC 3’ 
(primer 1) and the reverse primer 5’ C ATG CAC AAT GGG CCT GTG GCA TGC CAC 3’ (primer 2). In 
parallel, we amplified the sequence of Pex13 transmembrane domain present in MAVS-Pex using 
the forward primer 5’ GC CAC AGG CCC ATT GTG CAT GCA TTT GCC 3’ (primer 3) and the primer 
reverse 5’ G GGGTAC CTC GAG TTA AGA TTT TGC TGA GG 3’ (primer 4). After purifying the 
reaction products of each PCR, both were used as a template for the last reaction, together with 
primer 1 and primer 4, resulting in MAVS511Pex sequence. These two last primers were designed 
with restriction sites that allowed the construct insertion into the pCMV-3C vector. The PCR 
conditions for each reaction are presented in Table 5.  
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Table 5 | PCR conditions of MAVS-511-Pex insert cloning 
NS3/4A 
NS3/4A was kindly provided by Dr. Eliane Meurs (Institut Pasteur, France), however for this work 
it had to be inserted in a pEGFP-C1 vector. For this, primers were design to contain the 
appropriate restriction sites, primer forward 5’ C CC CAA GCT TGG ATG GCG CCC ATC ACC 3’ and 
primer reverse 5’ G GGG TAC CTC GAG TTA GCA CTC TTC CAT CTC 3’. The NS3/4A was amplified 
using the program detailed in table 6.  
Table 6 | PCR conditions of NS3/4A cloning. 
Steps PCR –NS3/4A 
Initialization 1x 95°C 2:00 
Denaturation 
4x 
94°C 0:30 
Annealing 48°C 0:30 
Extension 70°C 2:00 
Denaturation 
25x 
94°C 0:30 
Annealing 65°C 0:30 
Extension 70°C 2:00 
Elongation 1x 70°C 0:30 
Final Hold 4⁰C ∞ 
All the reactions were carried in a thermal cycler (BioRad) using the KOD Hot Start DNA 
Polymerase (Novagen). 
DNA electrophoresis and isolation 
In the end of each PCR reaction the products of interest were isolated by DNA electrophoresis 
which ran in a 0.7% agarose gel in 1x TAE, stained with 0.5 μg/mL of ethidium bromide, at 70 V for 
Steps PCR 1 PCR 2 PCR 3 
Initialization 1x 95°C 2:00 1x 95C 2:00 1x 95°C 2:00 
Denaturation 
4x 
94°C 0:30 
5x 
94°C 0:30 
5x 
94°C 0:30 
Annealing 50°C 0:40 43°C 0:30 52°C 0:30 
Extension 70°C 1:40 70°C 0:30 70°C 3:00 
Denaturation 
30x 
94°C 0:30 
25x 
94°C 0:30 
25x 
94°C 0:30 
Annealing 65°C 0:30 65°C 0:30 65°C 0:30 
Extension 70°C 1:40 70°C 0:30 70°C 3:00 
Elongation 1x 70°C 10:00 1x 70°C 10:00 1x 70°C 10:00 
Final Hold 4⁰C ∞ 4⁰C ∞ 4⁰C ∞ 
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1 hour and 30 min in 1x TAE running buffer. To follow sample’s running, they were mixed with a 
loading dye (Fermentas) and a DNA maker (Fermentas) was loaded to allow sizing and 
quantification. Photos were taken using the GelDoc (BioRad) and treated with the Image Lab 
(BioRad) program. The bands of interest were excised under the UV light with a scalpel. They were 
isolated and purified with NucleoSpin Gel and PCR clean-up (Macherey-Nagel) as the protocol 
indicates.  
Restriction digestion and ligation 
Inserts (MAVS511Pex and NS3/4A) and vectors (pEGFP-C1) were digested with the restriction 
enzymes Hind III, Kpn I (New England Biolabs) in the Nebuffer 2 (New England Biolabs) at 37°C for 
3 hours.  
The fragments were then separated by DNA electrophoresis as described above with a 1% 
agarose gel in 1x TAE, at 75 V for 1 hour and purified with the same kit. In the end, samples were 
quantified with the program Image lab (BioRad). 
The vector-insert ligation was performed in a molecular ratio of 1:3 (Figure 8) and both were 
incubated with a T4 DNA ligase in NEBuffer U (New England Biolabs) at 16°C overnight.  
 
Figure 8 | Formula used to calculate insert quantity for ligation protocol  
Bacterial transformation 
For bacterial transformation, 50 μL of competent E.coli XL Blue were mixed with 5 μL of ligation 
DNA and incubated for 30 minutes on ice. After the heat shock at 42°C for 90 seconds and 3 
minutes on ice, bacteria recuperated in 950 μL of LB for 45 minutes at 37°C and at 200rcf. Then, 
bacterial suspension centrifuged for 1 minute at 1700rcf and some supernatant was discarded. 
The pellet was resuspended in the remaining supernatant and glass beads helped to spread 
bacterias in LB/agar/kanamycin plates. An incubation at 37°C overnight followed. The protocol 
was done under a sterile environment and the appropriate controls were used.  
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Colony selection 
Several test colonies were inoculated in 3 mL of LB medium (with kanamycin) for 16 hours at 37°C 
with shaking (200rcf). Plasmid isolation was accomplished through a miniprep protocol based in 
alkaline lysis. 1.5mL of each bacterial suspension was centrifuged at 12000 rcf during 2 minutes. 
The pellet was lysed in 100 μL of cold solution I and vortexed vigorously before desnaturation in 
200 μL of solution II. Then, it was inverted 5 times and incubated for 5 minutes with 150 μL of cold 
solution III before being centrifuged at 17000 rcf for 10 minutes at 4°C. To precipitate and purify 
the DNA, the supernatant was discarded and 1 mL of ethanol was added. Samples were 
centrifuged at 17000 rcf during 5 minutes at 4°C and the supernatant was once again discarded. 
After drying the pellet at room temperature, it was rehydrated in 50 μL of water with RNase. 
To define which colonies were positive, two restriction analysis with the same conditions as 
described above were performed. A positive colony was selected and purified using the 
NucleoSpin Plasmid kit (Macherey-Nagel). The manufacture’s protocol was followed. 
To insert MAVS511Pex in the pCMV-3C vector it was necessary to do an enzymatic restriction in 
the GFP-MAVS511Pex and in the pCMV-3C vector with HindIII and XhoI restriction enzymes in 
NeBuffer2 for 3 hours at 37°C. Afterwards, the previously described procedure was followed from 
ligation up to the purification. 
Sequencing 
To confirm the sequence of each construct, they were sent for sequencing at Eurofins MWG 
Operon (Germany). For that, suspension cultures in 4 mL of LB medium (with kanamycin) were 
prepared from each positive colonies of pEGFP-C1-MAVS511Pex, pCMV-3C-MAVS511Pex, pEGFP-
C1NS3/4A. After incubating for 16h at 37°C with shaking (200rcf), the DNA was isolated using the 
protocol provided by NucleoSpin Plasmid, Macherey-Nagel. After quantification, the samples 
were sent to be sequenced. The sequences were analysed with the FinchTV 1.4.0 program 
(Geospiza) and compared with the original sequences using the Basic Local Alignment Search 
(BLAST) Tool from National Center for Biotechnology Information (NCBI). 
After sequence confirmation, high quality plasmids were grown in high quantity for transfection. 
3mL of each culture were add to 200 mL of LB medium (with kanamycin) and incubated for 16 
hours at 37°C with shaking (200rcf). Then, the plasmids were purified following the NucleoBond® 
Xtra Midi (Macherey-Nagel) protocol. 
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3.2.2. Cell culture 
 Cell Maintenance 
The cells chosen for this project were the Mouse Embryonic Fibroblasts (MEF) cells with a knock-
out of MAVS protein (MEF KO MAVS). These cells were kindly provided by Dr. Kagan (Harvard 
Medical School, Boston) and were used for all the experiments presented. 
MEF KO MAVS were routinely cultured in DMEM high glucose (4,5 g/L) supplemented with 10% 
FBS, 100U/mL penicillin and streptomycin at 37°C in a humidified atmosphere containing 5% CO2. 
After reaching the desired confluence, cells were passed and split twice a week. Confluent cells 
were washed with PBS and after incubating 1 minute with 2 mL trypsin-EDTA at 37°C and 5% CO2 
they were harvested with 6 mL of cell culture medium and centrifuged at 1000 rcf for 3 minutes at 
room temperature. Upon resuspention of the cell pellet in 10 mL of cell culture medium, cells 
were seeded in a 1:10 dilution (≈105 cells/mL). Cells were routinely grown on 10øcm culture 
dishes. For the immunofluorescence studies, cells were seeded on 6øcm dishes with 5 round 
18ømm glass coverslips and for the immunoblotting and RT-qPCR experiments 6 well plates were 
used.  
 Cell storage, freezing and thawing 
Cells stocks were kept in liquid nitrogen for cryopreservation. Stocks were prepared from 
confluent cells as described above and resuspended in freezing medium (DMEM supplemented 
with 20% FBS and 10% DMSO). Cells were preserved in cryovials aliquots of 1 mL and frozen 
overnight in -80° before being placed in the liquid nitrogen tank. 
When needed, cells were thawed through resuspention with pre-warmed culture medium and 
seeded in a 10øcm culture dishes. After cell adhesion (≈ 5 hours) the medium was changed to 
remove cell debris and DMSO. 
3.2.3. Transfection methods 
 Lipofectamine 3000 
Two reactions were prepared: first, 8 μL Lipofectamine 3000 reagent was diluted in 250 μL Opti-
Mem and in a second one DNA was diluted with 8 μL P3000 in 250 μL Opti-Mem. After 5 minutes 
of incubation at room temperature the second reaction was added to the first and incubated for 
more 5 minutes in the same conditions. Then, the DNA/reagent complex was added drop-wise to 
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6øcm culture dishes and incubated for 4 hours at 37°C after which the cells were washed with PBS 
and incubated for more 24 hours in fresh culture medium. Different quantities of DNA were used, 
6μg of Myc-MAVS-511-Pex, 6 μg of Myc-MAVSWt and/or 8 μg of Gfp-NS3/4A.  
 Golden Needle Microporation 
Cells at a density of 5x106 were resuspended in Resuspension Buffer R. After adding 10 μg of DNA 
to the cell suspension, cells were microporated using the Neon Transfection System with 1 pulse 
in 3 mL of Electrolytic Buffer E with a 10 μL Neon Tips. Microporation pulse conditions were 1350 
V for 30 seconds. Cells were then incubated in 6øcm culture dishes with 10mL of culture medium 
with FBS and without antibiotics for 6 hours at 37°C before changing to complete medium. 
3.2.4. Immunofluorescence 
Cells grown in glass coverslips were washed three times with PBS before being fixated for 20 
minutes with 4% para-formaldehyde, permeabilized with 0,2% Triton X-100 for 10 minutes, and 
blocked with 1% BSA for 10 minutes. Cells were stained with 30 μL of the primary antibody as well 
as with the secondary antibody for 1 hour in a humid environment, protected from the light. 
Finally, coverslips were incubated with 30 μL of Hoechst dye for 2 minutes. All the incubations 
were done at room temperature and, between each step the cells were washed three times with 
PBS. Coverslips were washed in ddH2O, mounted in glass slides with mounting medium and dried 
for at least 24 hours. Glass slides were stored at 4°C. 
For these experiments, the cells were observed with an Olympus IX-81 inverted (Olympus Opical 
Co.) microscope, 100x/1.40 oil objective (Olympus Optical) equipped with the appropriate filter 
combinations and a 100x objective (Plan-Neofluar, 100x/1.35 oil objective). Confocal photos were 
acquired with a Leica TCS SP5 confocal microscope, Plan-Apochromat 63x and 100x/1.40 oil 
objectives (Leica), using the LAS AF LITE (Leica). The lasers used were 488 nm Argon-ion laser, 561 
nm DPSS laser and 642 nm HeNe for samples stained with Alexa Fluor 488 dye, TRITC dye and 
Alexa 647 dyed, respectively. 
3.2.5. Immunoblotting 
 Lysis and harvesting 
Cells were seeded 48 hours in 6øcm dishes and transfected 24 hours before being washed three 
times with PBS. Then, after being harvested with 200 μL of lysis buffer and a scrapper, the 
samples were resuspended 20 times with a 26G syringe. An incubation for 30 minutes at 4°C with 
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head-rotation was performed and the samples centrifuged for 15 minutes at 13 000 rcf in 4°C. The 
collected supernatant was stored at -20°C. 
For measurement of the samples’ protein concentration, the Bradford protein assay was 
performed. The bradford reagent was diluted (1:5) with ddH2O and a series of BSA standards were 
prepared in duplicate with known protein concentrations (1 μg/μL BSA diluted in 1 M NAOH: 0.01-
0.11 μg/μL). To measure the samples 0,3 μL of protein extract was diluted in 1 M NAOH. After 
adding 1 mL of Bradford, the dilutions were incubated for 15 minutes at room temperature. After, 
standards and the samples absorbance were measured at 595 nm with a Spectrophotometer 
(VWR), a standard curve was draw in Excel program (Microsoft) and samples concentration was 
calculated.  
 Protein electrophoresis and blotting 
50 μg of protein extracts diluted in 5x loading buffer incubated for 15 minutes at 65°C. Samples 
were loaded alongside with a pre-stained protein marker (Nzytech) in mini handcast gels 
prepared with 7% polyacrylamide resolving gel and 4% stacking gel. The gel chamber was filled 
with running buffer and electrophoresis was conducted in running buffer for 1 hour and 30 
minutes at 150 V. Bromophenol blue presented in the loading buffer allowed sample running 
visualization. 
After protein’s separation, the gel was assembled with a nitrocellulose membrane and Whatman 
filter paper in a mini trans-blot system. After equilibrating all the components in transfer buffer, 
they were set in a specific order: foam pad, filter paper, gel, membrane, filter paper and foam pad 
inside the cassette. To ensure the transfer, air bubbles that could had form were taken by 
pressing all the components. The chamber was filled with transfer buffer and the blotting was 
conducted at 0.4 A for 2 hours on ice. 
 Immunodetection 
After blotting, the membrane was washed to take out methanol residue before being blocked 
with 5% low fat powder milk in TBS-T for 50 minutes. Membrane staining was accomplish by 
incubation with a primary antibody, for 1 hour to 3 hours depending on the antibody, and a 
secondary antibody, for 1 hour, both at room temperature with shaking. Between incubations, 
three washing steps of 10 minutes each with TBS-T were performed.  
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For enhanced chemiluminescence detection, membrane was incubated with a chemiluminescent 
substrate solution, a mixture 1:1 of luminol and peroxide from the Clarity Western ECL Substrate 
kit (BioRad), for approximately 3 minutes before exposing to a photographic film for 30 seconds 
to 10 minutes. Exposition, fixation and development occurred in a light protected environment. 
Photos were taken with a Densitometer (BioRad) and analysed with the Quantity One (BioRad) 
software. 
3.2.6. Reverse transcriptase - quantitative Polymerase Chain Reaction  
 RNA extraction 
Cells were washed with PBS and lysed by incubating 5 minutes at room temperature with 500 μL 
Trifast/Trizol before collection. 100 μL of chloroform were added and the samples were shaken 
vigorously for 15 seconds and incubated for more 5 minutes at room temperature. Following a 
centrifugation for 15 minutes at 12000 rcf, the upper aqueous phase containing RNA was 
extracted. RNA was incubate with 250 μL of isopropanol for 10 minutes. After centrifugation for 
15 minutes at 12000 rcf, the supernatant was removed. The pellet was washed two times with 
500 μL of 75% ethanol and centrifuged for 5 minutes at maximum speed. After removing the 
ethanol, the pellet dried for 10 minutes before being resuspended with 30  μL of RNAse free 
water.  
The RNA concentration was measured with Nanodrop after being dissolved at 55°C and RNA 
quality was also assessed by electrophoresis. The RNA mixed with loading dye ran in a 1% agarose 
gel stained with Midori Green for 1 hour at 100V.  
 cDNA synthesis 
cDNA synthesis was accomplished by mixing 2μg RNA with a master mix of 280 pmol oligo-dT 
primer, 166 μM dNTPs, 1x M-MuL V Reverse transcriptase buffer, 100 U M-MuL V Reverse 
transcriptase, 20 U RNAse inhibitor and RNAse free water . This mixture incubated for 10 minutes 
at room temperature. Then, cDNA was synthesised for 90 minutes at 42°C and the enzyme was 
inactivated for 20 minutes at 65°C.  
Real-time Quantitative Polymerase Chain Reaction 
The primer sequences used for quantification of IRF1 were 5’ GGTCAGGACTTGGATATGGAA 3’ and 
5’ AGTGGTGCTATCTGGTATAATGT 3’, for viperin were 5’ TGTGAGCATAGTGAGCAATGG 3’ and 5’ 
TGTCGCAGGAGATAGCAAGA 3’ and for GAPDH were 5’ AGTATGTCGTGGAGTCTA 3’ and 5’ 
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CAATCTTGAGTGAGTTGTC 3’. All sequences were designed using the Beacon Desigen 7 (Premier 
Biosoft) and GAPDH was used as a reference gene. The real-time polymerase chain reaction mix 
was prepared with 2 μL of 1:10 diluted synthesized cDNA, 10 μL of 2× iTaq SYBR Green Master 
Mix (BioRad) and each primer was added to a final concentration of 250 nM for a total volume of 
20 μL. Using the 7500 Real-Time PCR System (Applied Biosystems), the reaction initiated by 
heating at 95°C for 3 min, followed by 40 cycles of a 12 seconds denaturation step at 95°C and a 
30 seconds annealing/elongation step at 60°C. The fluorescence was measured after the 
extension step, using the Applied Biosystems software. After the thermocycling reaction, the 
melting step was performed with slow heating, starting at 60°C and with a rate of 1%, up to 95°C, 
with continuous measurement of fluorescence. Data analysis was performed using the 2−ΔΔCT 
method. 
3.2.7. Statistics 
For the quantitive analysis of IRF1 and viperin mRNA expression three independent experiments 
were done. Statistical analysis was performed in Graph Pad Prism 5. Data represent the means ± 
standard error mean (SEM). To determine the statistical significance between the experimental 
groups the one-way ANOVA followed by Bonferroni’s multiple comparison tests were applied. P 
values of ≤0.05 were considered as significant. 
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IV. Results 
4.1. Myc-MAVS511Pex and GFP-NS3/4A plasmids contruction   
MAVS was first discovered to localize at mitochondria and more recently Dixit et al. (2010) have 
shown that it is also present at peroxisomes (67). In both organelles, MAVS acts as a signalling 
transducer in the immune response against infection triggered by the activation of RIG-I and/or 
MDA5 upon  recognition of viral genomes (63–65,67,71). Furthermore, it was also found that the 
presence of MAVS in both organelles has different but complementing functions: peroxisomal 
MAVS induces a rapid but short-termed interferon-indendent response, which contrasts with the 
delayed kinetics and interferon-dependent response by the mitochondrial MAVS pathway (67).  
We have received specific constructs from Kagan’s laboratory (Harvard Medical School, USA) in 
which the MAVS localization motif was replaced with a set of domains that redirect the protein to 
peroxisomes or mitochondria (67). During the process of construction of these plasmids, the Cys-
508 that is recognized by HCV NS3/4A  was deleted (47). To study the possible effect of NS3/4A in 
peroxisomal MAVS, the plasmid encoding for the peroxisomal MAVS had, hence, to be modified 
and was altered so that the Cys-508 was re-introduced. Thus, we had to do a series of PCRs using 
MAVS-WT (also kindly provided by Dr. Kagan) and MAVS-Pex as templates. We started by 
amplifying the MAVS-WT sequence that encodes the first 511 aa. In parallel, a second PCR using 
the MAVS-PEX was performed in order to amplify the sequence that encodes the transmembrane 
domain of Pex13. Lastly, both PCR products were combined as template of the final PCR reaction 
resulting in MAVS511Pex construct (Figure 9, for further details on the reactions please see 
section 3.2.1). MAVS511Pex corresponds to the MAVS-Pex described by Dixit et al. (2010), with 
the extra original sequence between aa 500 and 511, necessary for NS3/4A cleavage (Figure 10A). 
This construct was developed  with the necessary restriction sites in order to be inserted in the 
pCMV-3C (Figure 10B) and be express fused to a Myc-tag. 
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Figure 9 | Schematic representation of MAVS511Pex construction. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 | MAVS511Pex. A) Schematic representation of MAVS511Pex domains. B) Schematic representation of 
plasmid pCMV-3C-MAVS511Pex. 
 
A 
    
 
B 
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To verify the localization of the newly made Myc-MAVS511Pex, the plasmid was overexpressed in 
mouse embryonic fibroblasts (MEFs) that were genetically altered to not express the MAVS 
protein in any organelle – MEF KO MAVS (Dixit et al 2010). These cells were then transfected by 
microporation with Myc-MAVS511Pex and were subjected to immunofluorescence analysis with 
antibodies against the peroxisomal marker PMP70 and Myc. Analysis by confocal microscopy 
showed that MAVS511Pex co-localized with peroxisomes (Figure 11). 
 
 
Figure 11 | MAVS511Pex co-localizes with peroxisomes. (a-c) Mefs KO MAVS cells transfected with Myc-MAVS511PEX; 
(a) Myc-MAVS511Pex, (b) PMP70, (c) merge image. Scale bar corresponds to 10μm. 
 
HCV NS3/4A protease is a complex formed by two proteins: NS3 serine protease and the NS4A co-
factor.  Dr. Eliane Meurs (Institut Pasteur, France) kindly provided a NS3/4A construct inserted in 
the vector pcDNA3.1-/Hygro(-)T7-Tag-. However for this work we decided to insert it in a pEGFP-
C1 vector in order to express the NS3/4A in conjugation with a GFP-tag (Figure 12A). We then 
amplified the NS3/4A sequence flanked with specific restriction sites in order to insert it into the 
pEGFP-C1. To confirm the expression and the cytosolic localization, GFP-NS3/4A was 
overexpressed in MEFs KO MAVS cells by Lipofectamine 3000. Cells were subjected to 
immunofluorescence analysis (Figure 12B) and photos were taken by confocal microscopy.  
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Figure 12  | GFP-NS3/4A. A) Graphic of pEGFP-C1-NS3/4A. B) GFP-NS3/4A expression. (a) Mefs KO MAVS cells 
transfected with GFP-NS3/4A. Scale bar corresponds to 10μm. 
4.2. Peroxisomal MAVS is cleaved by HCV NS3/4A 
The first reports showing the existence of MAVS at mitochondria also reported that this protein is 
targeted by the HCV NS3/4A complex (47,64,104). However, none of these reports investigated 
the effect of NS3/4A on the peroxisomal MAVS. To clarify whether the NS3/4A complex is able to 
similarly cleave the peroxisomal MAVS, Myc-MAVS511Pex was overexpressed in MEFs KO MAVS 
together with GFP-NS3/4A. Cells were co-transfected by microporation and fixed cells were 
subjected to immunolocalization with antibodies against Myc and Pex14, to mark Myc-
MAVS511Pex and peroxisomes, respectively.  
A 
                 
B  
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Analysing the co-expression of MAVS511Pex and NS3/4A by confocal microscopy it was clear that 
the MAVS localization changed from a peroxisomal to a cytosolic distribution, demonstrating that 
HCV NS3/4A is capable of cleaving the MAVS located at peroxisomes (Figure 13). In this image it is 
still possible to notice some co-localization between MAVS511Pex and peroxisomes (Figure 13: 
a,b,d – arrows indicate co-localization between Myc-MAVS511Pex and Pex14) as well as a co-
localization between NS3/4A and peroxisomes (Figure X: b,c,d – full-head arrows indicate co-
localization between GFP-NS3/4A and Pex14), indicating that at this point, not all the peroxisomal 
MAVS has yet been cleaved. 
 
Figure 13 | Peroxisomal MAVS redistributes to cytosol after cleavage by HCV NS3/4A. (a-d) Mefs KO MAVS cells co-
transfected with Myc-MAVS511Pex and GFP-NS3/4A; (a) Myc-MAVS511Pex, (b), Pex14, (c) GFP-NS3/4A, (d) and merge 
image. Arrows indicate co-localization between Myc-MAVS511Pex and Pex14. Full-head arrows indicate co-localization 
between Pex14 and GFP-NS3/4A. Scale bar corresponds to 10μm. 
In parallel, the MAVS511Pex cleavage by NS3/4A was also analysed by immunoblotting. MEFs KO 
MAVS were co-transfected with Myc-MAVS511Pex and GFP-NS3/4A using Lipofectamine 3000. 
Alongside with MAVS511Pex, wild-type MAVS (Myc-MAVSWT) was also co-transfected with GFP-
NS3/4A as a control for the cleavage. In both conditions, the HCV NS3/4A construct 
overexpression resulted in both wild-type MAVS and peroxisomal MAVS cleavage. The products of 
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the cleavage are faster-migrant fragments that were ≈5 to 12kDa shorter than Myc-MAVSWT and 
Myc-MAVS511Pex, respectively (Figure 14).  
 
Figure 14 | Peroxisomal MAVS is cleaved by NS3/4A. Mefs KO MAVS cells co-transfected with Myc-MAVSWT or Myc-
MAVS511Pex and GFP-NS3/4A. Arrow indicates the cleavage products of Myc-MAVSWT (lane 4) and Myc-MAVS511Pex 
(lane 6). 
4.2. Peroxisomal MAVS cleavage by HCV NS3/4A impairs cellular antiviral 
response 
In HCV infection, MAVS cleavage by NS3/4A complex leads to the inhibition of MAVS pathway and 
consequently to a decrease in type I IFN expression and ISGs production (64). Recent reports 
indicate that peroxisomal MAVS is responsible for the early induction of ISGs expression, such as 
viperin and IRF1. To examine the effect of NS3/4A on peroxisomal-MAVS, viperin and IRF1 
expression were quantified by RT-qPCR. We once again co-transfected MAVS511Pex and NS3/4A 
in MEFs KO MAVS as, since these cells do not express MAVS neither in mitochondria or in 
peroxisomes, the ISG expression will solely depend on the peroxisomal-MAVS pathway. To 
stimulate the antiviral response we transfected a RIG-I-CARD construct that only encodes the 
CARD domains of RIG-I allowing their direct exposition to MAVS without needing a activator 
ligand for RIG-I, hence mimicking a viral infection (61). Thus, MEF KO MAVS cells were co-
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transfected with Myc-MAVS511Pex and GFP-NS3/4A for 24 hours, and stimulated with GFP-RIG-I-
CARD for 6 hours. For both IRF1 and viperin, a clear decrease in mRNA production was observed 
(Figure 15). 
 
Figure 15 | Peroxisomal MAVS cleavage by NS3/4A impairs IRF1 and viperin expression. (a-b) Mefs KO MAVS cells 
were co-transfected with Myc-MAVS511Pex and GFP-NS3/4A and stimulated with GFP-RIG-I-CARD. mRNA expression of 
(a) IRF1 and (b) viperin was analysed by RT-qPCR. Data represents the means ±SEM of three independent experiments. 
Statistical analysis was performed using one-way ANOVA followed by Bonferroni’s multiple comparison tests. Error bars 
represent SEM. *p≤0.05, compared with the MAVS511Pex condition considered as control. 
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V. Discussion 
During infection, cells detect non-self-molecules such as lipids, lipoproteins, proteins and nucleic 
acids, which present specific characteristics that allow their differentiation from the host cell 
molecules. Viruses release nucleic acids into the cytosol during viral replication, which are mainly 
recognized by cytosolic sensors from the RLR family that, when activated, transduce the signalling 
through the adaptor protein MAVS (57). The first reports on MAVS showed that it was located 
solely at the mitochondrial outer membrane but new data shows that it was also present at 
peroxisomes (63,67).  
One of the studies that identified MAVS as an adaptor protein in RIG-I antiviral pathway also 
showed that HCV NS3/4A is able to cleave it in order to inhibit IRF3 activation (64). They identified 
the Cys-508 as the target residue for MAVS cleavage by NS3/4A. Other study that described the 
action of NS3/4A over MAVS reported the action of NS3/4A on the mitochondrial outer 
membrane (47).  
In this study, we have developed a construct, the MAVS511Pex, that co-localized perfectly and 
solely with peroxisomes and allowed the specific study of the effect of HCV NS3/4A directly over 
the peroxisomal-MAVS pathway. Our results show that HCV NS3/4A is also capable of cleaving the 
MAVS localized at peroxisomes, as the presence of this viral protein resulted in the cleavage of 
MAVS at Cys-508 and dislocation of MAVS from peroxisomes to the cytosol, similarly to what had 
previously been shown to occur at the mitochondrial MAVS (63,64,68).  Our data also shows some 
degree of co-localization of NS3/4A with peroxisomes, demonstrating its binding to the 
peroxisomal membrane in order to specifically cleave MAVS.   
The reports on mitochondrial-MAVS inhibition by NS3/4A have shown that this causes an 
inhibition of the downstream signal transduction leading to a decrease in type I IFN expression 
and, consequent, inhibition of ISGs expression (47,64,105). However, these reports reflect the 
result of NS3/4A on the total MAVS present in the cell, until then thought to be only at 
mitochondria. In this work, besides showing that NS3/4A is also capable of cleaving MAVS 
exclusively at peroxisomes, we demonstrate that this cleavage clearly inhibits the peroxisomal-
dependent downstream pathway by showing a decrease in IRF1 and viperin expression.  
In our experiments, the MAVS pathway was stimulated by overexpression of a constitutively 
active form of RIG-I (RIG-I-CARD) where its CARD domain is exposed. Naturally, these results 
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should be validated upon HCV infection or in a specific cell model that stability expresses a HCV 
replicon.  
The antiviral defence set by the activation of MAVS is dependent on its localization but both 
responses complement each other: the peroxisomal MAVS induces a rapid but short-termed IFN-
independent response, whereas the mitochondrial MAVS activates a IFN-dependent response 
with delayed kinetics (67). The discovery of peroxisomal-MAVS targeting by HCV NS3/4A protease 
raised a question concerning the specificity of this targeting: could HCV set a specific inhibition at 
peroxisomal MAVS by cleaving it first, thus directly affecting the early antiviral response? As 
future work, one should investigate the sequence of events associated to the targeting of 
peroxisomal and mitochondrial MAVS by NS3/4A. For this, a similar construct to MAVS511Pex 
that targets this protein solely to mitochondria should be designed (MAVS511Mito). By co-
transfecting the MAVS511Pex, MAVS511Mito and NS3/4A, one would be able to analyse which of 
the two proteins would be cleaved first. NS3/4A complex has several functions in HCV life cycle 
mainly due to its protease activity. Several other viruses produce similar complexes that impair 
MAVS pathways and some were already linked to its inhibition, such as Enterovirus (106), 
Poliovirus (106), Hepatitis A virus (107), and others. To better understand the importance of 
peroxisomal MAVS in the innate immune response against viruses it should be investigated 
whether these viruses also specifically target the peroxisomal MAVS impairing the associated 
antiviral signalling pathway. 
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VI. Final Remarks 
6.1. Conclusions 
Peroxisomes are important organelles in human health being responsible for many cellular 
metabolic pathways such as lipid metabolism. Their dysfunction or absence is associated with 
genetic disorders that can be fatal. The identification of MAVS at peroxisomes conferred to 
peroxisomes a new role in health and disease, particular in the innate immune response. MAVS is 
also present at mitochondria, accentuating the interconnection between these two organelles, 
long-time partners in several metabolic pathways.  
HCV is a major human viral pathogen that infects hepatocytes and is highly dependent of on lipid 
metabolism. HCV has evolved specific mechanisms to overcome the cellular innate immune 
response. NS3/4A is a viral protease complex that targets adaptor proteins – MAVS and TRIF – 
coordinating the antiviral response induced by RLR and TLR3, respectively. 
The main conclusion of this work is that the HCV NS3/4A protease cleaves peroxisomal MAVS, 
impairing the peroxisome-dependent cellular antiviral response (Figure 16) (47,64).  
 
Figure 16 | Schematic representation of MAVS signalling pathway and interaction of HCV NS3/4A (67,71,72). 
? 
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6.2. Publications resulting from this work 
Ferreira A R, Magalhães A C, Gouveia A, Vieira M, Camões F, Kagan J, Ribeiro D. Hepatitis C virus 
NS3/4A inhibits peroxisomal MAVS-dependent antiviral signaling response. (manuscript in 
preparation to be submitted to Cell Host & Microbe)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ana Rita Filgueiras Ferreira 
68 
 
 
Hepatitis C virus and Peroxisomes: evasion from the cellular antiviral response 
69 
 
 
VII. References 
Ana Rita Filgueiras Ferreira 
70 
 
 
Hepatitis C virus and Peroxisomes: evasion from the cellular antiviral response 
71 
 
 
1.  Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA 
clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 
21;244(4902):359–62.  
2.  WHO | Hepatitis C [Internet]. Fact Sheet No 164. World Health Organization; 2014 [cited 
2014 Jun 10]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/ 
3.  Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 
2006 Jan;3(2):47–52.  
4.  Gottwein JM, Bukh J. Cutting the gordian knot-development and biological relevance of 
hepatitis C virus cell culture systems. Adv Virus Res. 2008 Jan;71(08):51–133.  
5.  Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by 
augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. 
Hepatology. 2011 Jan;53(1):32–41.  
6.  Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV 
infection. Nat Rev Gastroenterol Hepatol. Nature Publishing Group; 2011 May;8(5):257–
64.  
7.  Schoggins JW, Rice CM. Innate Immune Responses to Hepatitis C Virus. In: Bartenschlager 
R, editor. Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. Berlin, 
Heidelberg: Springer Berlin Heidelberg; 2013. p. 219–42.  
8.  Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly 
effective therapies. Nat Med. Nature Publishing Group; 2013 Jul;19(7):837–49.  
9.  Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006 Jun 
26;25(27):3834–47.  
10.  Chevaliez S, Pawlotsky J-M. HCV Genome and Life Cycle. In: Tan S, editor. Hepatitis C 
Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience; 2006. p. 5–47.  
11.  Suzuki T. Morphogenesis of infectious hepatitis C virus particles. Front Microbiol. 2012 
Jan;3:38.  
12.  Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, et al. Ultrastructural analysis 
of hepatitis C virus particles. Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9505–10.  
13.  Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone 
of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. 
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8738–43.  
14.  Tariq H, Manzoor S, Parvaiz F, Javed F, Fatima K, Qadri I. An overview: in vitro models of 
HCV replication in different cell cultures. Infect Genet Evol. Elsevier B.V.; 2012 
Jan;12(1):13–20.  
Ana Rita Filgueiras Ferreira 
72 
 
15.  Lohmann V. Hepatitis C: Methods and Protocols. Tang H, editor. Totowa, NJ: Humana 
Press; 2009;510:145–63.  
16.  Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life 
cycle. Nat Rev Microbiol. 2005 Jan;3(1):13–22.  
17.  Merz A, Long G, Hiet M-S, Brügger B, Chlanda P, Andre P, et al. Biochemical and 
morphological properties of hepatitis C virus particles and determination of their lipidome. 
J Biol Chem. 2011 Jan 28;286(4):3018–32.  
18.  Gastaminza P, Dryden K a, Boyd B, Wood MR, Law M, Yeager M, et al. Ultrastructural and 
biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol. 
2010 Nov;84(21):10999–1009.  
19.  Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus 
particles. Trends Microbiol. 2011 Feb;19(2):95–103.  
20.  Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007 
Jun;5(6):453–63.  
21.  Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their 
biological functions. J Gen Virol. 2006 May;87(Pt 5):1075–84.  
22.  Bartosch B, Cosset F-L. Cell entry of hepatitis C virus. Virology. 2006 Apr 25;348(1):1–12.  
23.  Zhu Y-Z, Qian X-J, Zhao P, Qi Z-T. How hepatitis C virus invades hepatocytes: the mystery of 
viral entry. World J Gastroenterol. 2014 Apr 7;20(13):3457–67.  
24.  Hoffman B, Liu Q. Hepatitis C viral protein translation: mechanisms and implications in 
developing antivirals. Liver Int. 2011 Nov;31(10):1449–67.  
25.  Shi ST, Lai MMC. HCV 5’ and 3' UTR: When Translation Meets Replication. In: Tan S, editor. 
Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience; 
2006. p. 49–87.  
26.  Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. 
Nature. 2005 Aug 18;436(7053):933–8.  
27.  Fauvelle C, Felmlee DJ, Baumert TF. Unraveling hepatitis C virus structure. Cell Res. Nature 
Publishing Group; 2014 Apr;24(4):385–6.  
28.  Kim CW, Chang K-M. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 
2013;(19):17–25.  
29.  Egger D, Wölk B, Gosert R, Blum HE, Moradpour D, Bienz K, et al. Expression of Hepatitis C 
Virus Proteins Induces Distinct Membrane Alterations Including a Candidate Viral 
Replication Complex. J Virol. 2002;76(12):5974–84.  
Hepatitis C virus and Peroxisomes: evasion from the cellular antiviral response 
73 
 
30.  Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, et al. Identification of 
the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic 
Replicons. J Virol. 2003;77(9):5487–92.  
31.  Penin F, Dubuisson J, Rey F a, Moradpour D, Pawlotsky J-M. Structural biology of hepatitis 
C virus. Hepatology. 2004 Jan;39(1):5–19.  
32.  Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol. 2000 Jul;81(Pt 
7):1631–48.  
33.  Tang H, Grisé H. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci 
(Lond). 2009 Jul;117(2):49–65.  
34.  Moriishi K, Matsuura Y. Host factors involved in the replication of hepatitis C virus. Rev 
Med Virol. 2007;17(5):343–54.  
35.  Enomoto N, Sato C. Hepatitis C virus quasispecies populations during chronic hepatitis C 
infection. Trends Microbiol. 1995 Nov;3(11):445–7.  
36.  Liu HM, Aizaki H, Machida K, Ou J-HJ, Lai MMC. Hepatitis C virus translation preferentially 
depends on active RNA replication. PLoS One. 2012 Jan;7(8):e43600.  
37.  Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, McLauchlan J. Hepatitis 
C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-
dependent manner. Traffic. 2008 Aug;9(8):1268–82.  
38.  Suzuki T. Assembly of hepatitis C virus particles. Microbiol Immunol. 2011 Jan;55(1):12–8.  
39.  Tews BA, Popescu C-I, Dubuisson J. Last stop before exit - hepatitis C assembly and release 
as antiviral drug targets. Viruses. 2010 Aug;2(8):1782–803.  
40.  Targett-Adams P, Boulant S, Douglas MW, McLauchlan J. Lipid metabolism and HCV 
infection. Viruses. 2010 May;2(5):1195–217.  
41.  Lindebach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev 
Microbiol. 2013;11(10):688–700.  
42.  Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramière C, Bartenschlager R, et al. Secretion of 
hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive 
lipoproteins. PLoS One. 2009 Jan;4(1):e4233.  
43.  Jones DM, McLauchlan J. Hepatitis C virus: assembly and release of virus particles. J Biol 
Chem. 2010 Jul 23;285(30):22733–9.  
44.  Lin C. HCV NS3-4A Serine Protease. In: Tan S-L, editor. Hepatitis C Viruses: Genomes and 
Molecular Biology. Norfolk (UK): Horizon Bioscience; 2006. p. 163–206.  
Ana Rita Filgueiras Ferreira 
74 
 
45.  Moradpour D, Penin F. Hepatitis C virus: From structure to Function. In: Bartenschlager R, 
editor. Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. Springer-Verlag 
Berlin Heidelberg; 2013. p. 113–42.  
46.  Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM, et al. Regulation of interferon 
regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003 May 
16;300(5622):1145–8.  
47.  Li X-D, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves 
mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. 
Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17717–22.  
48.  Foy E, Li K, Sumpter R, Loo Y-M, Johnson CL, Wang C, et al. Control of antiviral defenses 
through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl 
Acad Sci U S A. 2005 Feb 22;102(8):2986–91.  
49.  Mawatari S, Uto H, Ido A, Nakashima K, Suzuki T, Kanmura S, et al. Hepatitis C Virus 
NS3/4A Protease Inhibits Complement Activation by Cleaving Complement Component 4. 
PLoS One. 2013 Jan;8(12):e82094.  
50.  Gao B, Jeong W-I, Tian Z. Liver: An organ with predominant innate immunity. Hepatology. 
2008 Mar;47(2):729–36.  
51.  Medzhitov R, Janeway C a. Innate Immunity: The Virtues of a Nonclonal System of 
Recognition. Cell. 1997 Oct;91(3):295–8.  
52.  Janeway C a, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002 
Jan;20(2):197–216.  
53.  Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res. 2006 Feb;16(2):141–
7.  
54.  Thompson MR, Kaminski JJ, Kurt-Jones E a, Fitzgerald K a. Pattern recognition receptors 
and the innate immune response to viral infection. Viruses. 2011 Jun;3(6):920–40.  
55.  Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006 
Feb;7(2):131–7.  
56.  Ranjan P, Bowzard JB, Schwerzmann JW, Jeisy-Scott V, Fujita T, Sambhara S. Cytoplasmic 
nucleic acid sensors in antiviral immunity. Trends Mol Med. 2009 Aug;15(8):359–68.  
57.  Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, et al. Shared and 
Unique Functions of the DExD/H-Box Helicases RIG-I, MDA5, and LGP2 in Antiviral Innate 
Immunity. J Immunol. 2005 Aug 22;175(5):2851–8.  
58.  Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006 
May;117(5):979–87.  
Hepatitis C virus and Peroxisomes: evasion from the cellular antiviral response 
75 
 
59.  Wilkins C, Gale M. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol. 
Elsevier Ltd; 2010 Feb;22(1):41–7.  
60.  Paludan SR, Bowie AG. Immune sensing of DNA. Immunity. Elsevier Inc.; 2013 May 
23;38(5):870–80.  
61.  Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA 
helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral 
responses. Nat Immunol. 2004 Jul;5(7):730–7.  
62.  Saito T, Gale M. Differential recognition of double-stranded RNA by RIG-I-like receptors in 
antiviral immunity. J Exp Med. 2008 Jul 7;205(7):1523–7.  
63.  Seth RB, Sun L, Ea C-K, Chen ZJ. Identification and characterization of MAVS, a 
mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell. 2005 Sep 
9;122(5):669–82.  
64.  Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is 
an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. 
Nature. 2005 Oct;437(7062):1167–72.  
65.  Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering 
RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol. 2005 Oct;6(10):981–
8.  
66.  Xu L-G, Wang Y-Y, Han K-J, Li L-Y, Zhai Z, Shu H-B. VISA is an adapter protein required for 
virus-triggered IFN-beta signaling. Mol Cell. 2005 Sep 16;19(6):727–40.  
67.  Dixit E, Boulant S, Zhang Y, Lee ASY, Odendall C, Shum B, et al. Peroxisomes are signaling 
platforms for antiviral innate immunity. Cell. Elsevier Ltd; 2010 May 14;141(4):668–81.  
68.  Horner SM, Liu HM, Park HS, Briley J, Gale M. Mitochondrial-associated endoplasmic 
reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis 
C virus. Proc Natl Acad Sci U S A. 2011 Aug;108(35):14590–5.  
69.  Hou F, Sun L, Zheng H, Skaug B, Jiang Q-X, Chen ZJ. MAVS forms functional prion-like 
aggregates to activate and propagate antiviral innate immune response. Cell. Elsevier Inc.; 
2011 Aug 5;146(3):448–61.  
70.  Xu H, He X, Zheng H, Huang LJ, Hou F, Yu Z, et al. Structural basis for the prion-like MAVS 
filaments in antiviral innate immunity. 2014;5:1–25.  
71.  Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, et al. Diverse intracellular 
pathogens activate type III interferon expression from peroxisomes. Nat Immunol. Nature 
Publishing Group; 2014 Jun 22;15(8):717–26.  
72.  Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, et al. Viral 
infections activate types I and III interferon genes through a common mechanism. J Biol 
Chem. 2007 Mar 9;282(10):7576–81.  
Ana Rita Filgueiras Ferreira 
76 
 
73.  Hiscott J. Convergence of the NF-kappaB and IRF pathways in the regulation of the innate 
antiviral response. Cytokine Growth Factor Rev. 2007 Jan;18(5-6):483–90.  
74.  Loo Y-M, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, et al. Viral and therapeutic 
control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad 
Sci U S A. 2006 Apr 11;103(15):6001–6.  
75.  Metz P, Reuter A, Bender S, Bartenschlager R. Interferon-stimulated genes and their role in 
controlling hepatitis C virus. J Hepatol. European Association for the Study of the Liver; 
2013 Aug 8;59(6):1331–41.  
76.  Horner SM, Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med. 
Nature Publishing Group; 2013 Jul;19(7):879–88.  
77.  Heim MH. Innate immunity and HCV. J Hepatol. European Association for the Study of the 
Liver; 2013 Mar;58(3):564–74.  
78.  Park S-H, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity. 
Elsevier Inc.; 2014 Jan 16;40(1):13–24.  
79.  Lazarow PB, Fujiki Y. Biogenesis of peroxisomes. Annu Rev Cell Biol. 1985 Jan;1:489–530.  
80.  Schrader M, Grille S, Fahimi HD, Islinger M. Peroxisome Interactions and Cross-Talk with 
Other Subcellular Compartments in Animal Cells. In: del Rio LA, editor. Peroxisomes and 
their Key Role in Cellular Signaling and Metabolism. Dordrecht: Springer Science & 
Business Media; 2013. p. 1–23.  
81.  Lodhi IJ, Semenkovich CF. Peroxisomes: A Nexus for Lipid Metabolism and Cellular 
Signaling. Cell Metab. Elsevier Inc.; 2014 Feb 5;19(3):380–92.  
82.  Islinger M, Schrader M. Peroxisomes. Curr Biol. 2011 Oct 11;21(19):R800–1.  
83.  Ribeiro D, Castro I, Fahimi HD, Schrader M. Peroxisome morphology in pathology. 
Histhology and Histhopathology. 2012;27(6):661–76.  
84.  Aubourg P, Wanders R. Peroxisomal disorders. 1st ed. Handbook of clinical neurology. 
Elsevier B.V.; 2013.  
85.  Wanders RJA. Metabolic functions of peroxisomes in health and disease. Biochimie. 
Elsevier Masson SAS; 2014 Mar;98:36–44.  
86.  Islinger M, Grille S, Fahimi HD, Schrader M. The peroxisome: an update on mysteries. 
Histochem Cell Biol. 2012 May;137(5):547–74.  
87.  Rucktäschel R, Halbach A, Girzalsky W, Rottensteiner H, Erdmann R. De novo synthesis of 
peroxisomes upon mitochondrial targeting of Pex3p. Eur J Cell Biol. 2010 Dec;89(12):947–
54.  
Hepatitis C virus and Peroxisomes: evasion from the cellular antiviral response 
77 
 
88.  Schrader M, Bonekamp N a, Islinger M. Fission and proliferation of peroxisomes. Biochim 
Biophys Acta. Elsevier B.V.; 2012 Sep;1822(9):1343–57.  
89.  Van der Zand A, Tabak HF. Peroxisomes: offshoots of the ER. Curr Opin Cell Biol. Elsevier 
Ltd; 2013 Aug;25(4):449–54.  
90.  Platta HW, Hagen S, Reidick C, Erdmann R. The peroxisomal receptor dislocation pathway: 
To the exportomer and beyond. Biochimie. Elsevier Masson SAS; 2014 Mar;98C:16–28.  
91.  Schrader M, Fahimi HD. The peroxisome: still a mysterious organelle. Histochem Cell Biol. 
2008 Apr;129(4):421–40.  
92.  Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Differ. 
2005 Nov;12:1542–52.  
93.  De Duve C, Baudhuin P. Peroxisomes (microbodies and related particles). Physiol Rev. 1966 
Apr 1;46(2):323–57.  
94.  Poirier Y, Antonenkov VD, Glumoff T, Hiltunen JK. Peroxisomal beta-oxidation - a metabolic 
pathway with multiple functions. Biochim Biophys Acta. 2006 Dec;1763(12):1413–26.  
95.  Wanders RJA. Peroxisomes in human health and disease: metabolic pathways, metabolite 
transport, interplay with other organelles and signal transduction. In: del Río LA, editor. 
Peroxisomes and their Key Role in Cellular Signaling and Metabolism. Vol 69. 2: Springer 
Science & Business Media; 2013. p. 23–44.  
96.  Delille HK, Bonekamp NA, Schrader M. Peroxisomes and disease - an overview. Int J 
Biomed Sci. 2006 Dec;2(4):308–14.  
97.  Bonekamp NA, Völkl A, Fahimi HD, Schrader M. Reactive oxygen species and peroxisomes: 
struggling for balance. Biofactors. 35(4):346–55.  
98.  Camões F, Islinger M, Guimarães SC, Kilaru S, Schuster M, Godinho LF, et al. New insights 
into the peroxisomal protein inventory: Acyl-CoA oxidases and -dehydrogenases are an 
ancient feature of peroxisomes. Biochim Biophys Acta. 2014 Oct 13;1853(1):111–25.  
99.  Del Río LA, Sandalio LM, Corpas FJ, Palma JM, Barroso JB. Reactive oxygen species and 
reactive nitrogen species in peroxisomes. Production, scavenging, and role in cell signaling. 
Plant Physiol. 2006 Jun;141(2):330–5.  
100.  Kirkman HN, Gaetani GF. Mammalian catalase: a venerable enzyme with new mysteries. 
Trends Biochem Sci. 2007 Jan;32(1):44–50.  
101.  Camões F, Bonekamp NA, Delille HK, Schrader M. Organelle dynamics and dysfunction: A 
closer link between peroxisomes and mitochondria. J Inherit Metab Dis. 2009 
Apr;32(2):163–80.  
102.  Lazarow PB. Viruses exploiting peroxisomes. Curr Opin Microbiol. Elsevier Ltd; 2011 
Aug;14(4):458–69.  
Ana Rita Filgueiras Ferreira 
78 
 
103.  Odendall C, Kagan JC. Peroxisomes and the Antiviral Responses of Mammalian Cells. In: del 
Río LA, editor. Peroxisomes and their Role in Cellular Signalling. Dordrecht: Springer 
Netherlands; 2013. p. 67–75.  
104.  Horner SM, Liu HM, Park HS, Briley J, Gale M. Mitochondial-associated endoplasmic 
reticulum membranes ( MAM ) form innate immune synapses and are targeted by 
hepatitis C virus. Proc Natl Acad Sci. 2011;108(35):14590–5.  
105.  Bellecave P, Sarasin-Filipowicz M, Donzé O, Kennel A, Gouttenoire J, Meylan E, et al. 
Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic 
hepatitis C correlates with a reduced activation of the endogenous interferon system. 
Hepatology. 2010 Apr;51(4):1127–36.  
106.  Feng Q, Langereis M a, Lork M, Nguyen M, Hato S V, Lanke K, et al. Enterovirus 2Apro 
targets MDA5 and MAVS in infected cells. J Virol. 2014 Mar;88(6):3369–78.  
107.  Yang Y, Liang Y, Qu L, Chen Z, Yi M, Li K, et al. Disruption of innate immunity due to 
mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci U S A. 
2007 Apr 24;104(17):7253–8.  
 
 
 
 
